WO2018186643A1 - Composition for reducing skin wrinkles, moisturizing skin, improving skin elasticity, exfoliating skin, inhibiting erythema or reducing skin photoaging, containing cinchonine or salt thereof as active ingredient - Google Patents

Composition for reducing skin wrinkles, moisturizing skin, improving skin elasticity, exfoliating skin, inhibiting erythema or reducing skin photoaging, containing cinchonine or salt thereof as active ingredient Download PDF

Info

Publication number
WO2018186643A1
WO2018186643A1 PCT/KR2018/003866 KR2018003866W WO2018186643A1 WO 2018186643 A1 WO2018186643 A1 WO 2018186643A1 KR 2018003866 W KR2018003866 W KR 2018003866W WO 2018186643 A1 WO2018186643 A1 WO 2018186643A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
composition
cinchonine
improving
expression
Prior art date
Application number
PCT/KR2018/003866
Other languages
French (fr)
Korean (ko)
Inventor
박태선
Original Assignee
연세대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 연세대학교 산학협력단 filed Critical 연세대학교 산학협력단
Publication of WO2018186643A1 publication Critical patent/WO2018186643A1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • A61K8/676Ascorbic acid, i.e. vitamin C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9706Algae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • A23V2200/318Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat

Definitions

  • the present invention relates to a cosmetic composition for improving skin wrinkles or enhancing elasticity comprising cinchonine or a cosmetically acceptable salt thereof as an active ingredient.
  • the skin is composed of three layers: epidermis, dermis and hypodermis.
  • the epidermis especially the stratum corneum, which is the outermost layer of the epidermis, acts as a skin barrier, inhibiting the loss of water and electrolytes from the skin.
  • the dermal layer plays a role in maintaining the elasticity of the skin and supporting the structure through collagen and elastin synthesis.
  • collagen and elastin are major proteins produced in fibroblasts and are involved in skin mechanical firmness, tissue cohesion and elasticity (Moskowit, RW et al, Role of collagen hydroiysate in bone and joint disease, Semin Arthritis Rheu, 30: 87, 2000).
  • Collagen forms various isoforms according to the form and structural features, and there are 28 kinds of collagen isotypes in human tissues. Among them, collagen is present in types 1, 3. 4. 6. 7. 13, 14, 17 and the like are known. Collagen types 1 and 3 make up the interstitial components of the dermal layer, and collagen type 7 is the major component of the dermal and epidermal junctions (Pei, M. et al., Expression of collagen type) I, II and III in loose body of osteoarthitis, J. Orthop. Sci., 5: 288, 2000).
  • Type I collagen is the largest amount of extracellular matrix protein in skin connective tissue, and other proteins such as elastin, fibronectin, integrin, fibrillin, and proteoglycan are present. do.
  • the newly synthesized procollagen is secreted into the extracellular space of skin cells through an enzymatic reaction to form a microfibril of triple helix configuration, and the microfibrils combine with leucine-rich small proteoglycans to form fibrils. As a result, these fibrils gather to form collagen fibers that provide skin binding and elasticity (Bateman, J.F. et al., Collagen superfamily.Extracellular matrix, Harwood, New York, 2, 22-26, 1996).
  • Skin aging is known to decrease collagen content, a protein that accounts for most of the collagen of skin dermis. Collagen decreases the skin's tension and strength. have.
  • Skin aging is largely divided into endogenous aging due to physiological aging and photoaging caused by continuous ultraviolet radiation (UV) exposure. Repeated ultraviolet exposure results in increased collagen degrading enzymes and causing denaturation and destruction of collagen fibers, reducing the elasticity of the skin and promoting the production of wrinkles.
  • ROS reactive oxygen species
  • increases continuously in skin tissues exposed to ultraviolet rays and the latter is a signaling system mediated by epidermal growth factor receptor (EGF-R), tumor necrosis factor (TNF) -receptor, etc. Schsenmaier, C.
  • MNK mitogen-activated protein kinase
  • MMPs ix metalloproteinases
  • skin elasticity is reduced and wrinkles are promoted (Kang, S. et al., Inflammation and extracellular matrix degradation mediated by activated transcription factors nuclear factor - ⁇ B and activator protein-l in Inflammatory acne lesions in vivo.Am J. Pathol., 166: 1691-1699, 2005).
  • AP-1 regulates the expression of numerous genes involved in cell growth and differentiation and strongly regulates the expression of some MMPs.
  • MMPs whose expression is regulated by AP-1, MMP-1 is known as collagenase 1, and is based on type 1 and 3 collagen.
  • the present invention is to provide a cosmetic composition for improving skin wrinkles or enhancing elasticity, including Cinchonine (Cinchonine) or a cosmetically acceptable salt thereof as an active ingredient.
  • the present invention provides a cosmetic composition for improving skin wrinkles or enhancing elasticity comprising cinchonine or a cosmetically acceptable salt thereof as an active ingredient.
  • the synonin is i) increased procollagen secretion, ii) decreased expression of matrix metalloproteinase (MMP) gene, iii) increased expression of collagen type alpha 1, ColI ⁇ 2 or Col3 ⁇ 1 or iv) elastin ( elastin) may increase the expression of the gene.
  • MMP matrix metalloproteinase
  • composition may further include at least one skin wrinkle improving component selected from the group consisting of vitamin C, retinoic acid, transforming growth factor (TGF), protein from animal placenta, betulinic acid and chlorella extract.
  • skin wrinkle improving component selected from the group consisting of vitamin C, retinoic acid, transforming growth factor (TGF), protein from animal placenta, betulinic acid and chlorella extract.
  • the present invention also provides a cosmetic composition for improving skin moisturizing, exfoliating, inhibiting erythema or improving skin photoaging, including cinchonine or a cosmetically acceptable salt thereof as an active ingredient.
  • the composition can inhibit thickening of the skin epidermal layer.
  • the composition can inhibit damage to the collagen fiber network of the skin epidermal-dermal bonds.
  • the present invention provides a health functional food composition for improving skin wrinkles or enhancing elasticity comprising Cinchonine or a food acceptable salt thereof as an active ingredient.
  • the present invention also provides a health functional food composition for improving skin moisturizing, exfoliating, inhibiting erythema or improving skin photoaging, including cinchonine or a food acceptable salt thereof as an active ingredient.
  • the present invention comprises the step of administering or taking a composition comprising Cinchonine (Cinchonine) or a salt thereof as an active ingredient to the subject to improve skin wrinkles, enhance elasticity, enhance skin moisturization, exfoliation, inhibit erythema or skin photoaging Provide ways to improve.
  • the present invention also provides a skin wrinkle improvement, elasticity enhancement, skin moisturization enhancement, exfoliation, erythema suppression or skin photoaging improvement of a composition comprising Cinchonine (Cinchonine) or a salt thereof as an active ingredient.
  • the present invention relates to a composition for improving skin wrinkles, enhancing elasticity, enhancing skin moisturizing, removing dead skin cells, inhibiting erythema or improving skin photoaging, including cinchonine or a salt thereof as an active ingredient, wherein the cinchonine is a fibroblast cell Promoting the secretion of procollagen in, it can increase the amount of activated collagen, increase the amount of collagen fibers in the dermal layer and inhibit the expression of MMPs genes that catalyze the breakdown of collagen, It can be used to improve skin wrinkles or to improve elasticity.
  • the cinconin increases the water content of the skin tissue and decreases the water evaporation amount, the skin moisturizing improvement effect, can suppress the erythema, can reduce the thickness of the thickened skin epidermal layer, exfoliation Or skin photoaging by ultraviolet rays etc. can be prevented.
  • Figure 1 shows the result of measuring the amount of procollagen secretion in human skin fibroblasts.
  • Figure 2 shows the results of measuring the weight gain and dietary intake of the mice ingested the experimental diet prepared according to Example 2, Comparative Examples 3 and 4.
  • Figure 3 shows the results of measuring the moisture content, elasticity and erythema index of the mouse skin tissue ingested experimental diet prepared according to Example 2, Comparative Examples 3 and 4.
  • Figure 4 is a photograph showing the back skin tissue of the mouse taking the experimental diet prepared in Example 2, Comparative Examples 3 and 4.
  • Figure 5 shows the results of measuring the degree of wrinkles of the skin tissue, such as the mouse taking the experimental diet prepared according to Example 2, Comparative Examples 3 and 4.
  • Figure 6 shows the results of measuring the skin thickness of the mouse taking the experimental diet prepared in Example 2, Comparative Examples 3 and 4.
  • Figure 7 shows the collagen fiber (collagen fiber) amount and morphological changes of mice fed the experimental diet prepared according to Example 2, Comparative Examples 3 and 4.
  • Figure 8 shows the expression changes of collagen and MMPs genes in the back tissue of hairless mice treated with Cinchonine according to the present invention.
  • Figure 9 shows the expression change of the elastin (Elastin) gene in the back tissue of the hairless mouse treated with Cinchonine according to the present invention.
  • the present inventors have found that by synonin promotes secretion of procollagen in dermal fibroblasts, increases the amount of collagen fibers in the dermal dermal layer, inhibits the expression of MMPs genes, promotes water content in skin tissues and inhibits water evaporation,
  • the present invention has been found to be effective in improving skin wrinkles, enhancing elasticity and enhancing skin moisturization, and reducing the erythema index and reducing the thickness of the thickened skin epidermal layer, thereby making it effective in inhibiting erythema and removing dead skin cells and improving skin photoaging.
  • skin improvement refers to maintaining or enhancing the capacity associated with wrinkles and elasticity of the skin.
  • Collagen (collagen) and elastic fiber elastin (collagen) in the dermal layer of the skin is the main protein that plays a role in the skin elasticity, collagen biosynthesis is affected by the internal and external skin.
  • the skin cells are reduced in cell activity due to natural aging, the collagen fibers are reduced, or the active oxygen generated by excessive irradiation of ultraviolet rays or stress as an external factor is the thiol group of the protein (thiol: -SH)
  • the enzyme activity or by increasing the expression of degradation enzymes, such as collagen, elastin, increase the wrinkles of the skin and decrease the elasticity, the skin aging progresses.
  • skin light aging refers to a physiological phenomenon in which the skin ages due to sun exposure (ultraviolet rays), and when exposed to the sun (ultraviolet rays) for a long period of time, deep wrinkles on the face and neck, and drying and The surface of the skin becomes rough or causes pigmentation such as spots and freckles.
  • the present invention provides a cosmetic composition for improving skin wrinkles or enhancing elasticity comprising cinchonine or a cosmetically acceptable salt thereof as an active ingredient.
  • the cinnacon is an alkaloid contained in a plant such as Cinchona, Cinona officinalis, Cinchona pubescens, Olive (Olea europaea), and Smilax china.
  • the structural formula is C 19 H 22 N 20
  • the molecular weight is 294.4 g / mol, it may be represented by the formula (1).
  • shinconin may include a sinconin hydrate, a sinconin derivative, and the like, and may also include a solvent compound or stereoisomer thereof.
  • the synonin is i) increased procollagen secretion, ii) decreased expression of matrix metalloproteinase (MMP) gene, iii) increased expression of collagen type alpha 1, ColI ⁇ 2 or Col3 ⁇ 1 or iv) elastin ( elastin) may increase the expression of the gene.
  • MMP matrix metalloproteinase
  • collagen a major protein constituting the skin
  • collagen is synthesized in the form of procollagen in fibroblasts present in the dermis and then secreted into the extracellular matrix.
  • the procollagen secreted into the extracellular matrix is present on the cell surface.
  • the C-terminus is decomposed by peptidase and converted into active collagen, the activated collagen content can be determined by measuring the C-peptide content.
  • the synonin may promote synthesis of procollagen in dermal fibroblasts, thereby increasing the amount of activated collagen.
  • MMPs matrix metalloproteinases
  • Nos. 1, 3 and 9 MMP types known to increase by UV rays
  • MMP types 1 and 3 MMP types known to increase by UV rays
  • MMP-1 the middle of the collagen fibers are cut and MMP-3 and MMP-9 serve to cut and cut the cut collagen fibers.
  • the cinconin according to the present invention can significantly inhibit the expression of the MMPs gene, thereby inhibiting the degradation of collagen fibers, and by increasing the synthesis of collagen protein in skin tissue, can inhibit wrinkle formation. .
  • the dermis of the skin is composed of collagen (collagen fiber) and elastin (elastic fiber).
  • the collagen fibers allow structural integration with skin tension formation, and elastin fibers can enhance skin elasticity by engaging in skin elasticity.
  • the syntholin according to the present invention promotes elastin expression, thereby exhibiting skin elasticity enhancing effect.
  • composition according to the present invention may further include at least one skin wrinkle improving component selected from the group consisting of vitamin C, retinoic acid, transforming growth factor (TGF), protein from animal placenta, betulinic acid and chlorella extract. It may be, but is preferably vitamin C, but is not limited thereto.
  • TGF transforming growth factor
  • the secretion of procollagen 20p% to when compared to the case of the single treatment with the neoconsin or vitamin C alone It can be seen that the 23p% increase, a significant synergistic effect was proved by Colby's formula.
  • Cinconin can effectively increase the amount of activated collagen as the secretion of procollagen increases in dermal fibroblasts compared to the case of using it alone.
  • the dose of cinconin is preferably included at a concentration of 0.1 ⁇ M to 1000 ⁇ M, but is not limited thereto.
  • the cinnaconin is less than the concentration range, the inhibition of MMPs gene expression catalyzing procollagen synthesis and collagen degradation is reduced, there is a problem that it is difficult to exert the effect of skin wrinkle improvement or elasticity enhancement, exceeding the concentration range If so, there may be toxicity concerns, including cytotoxicity.
  • the Cinconin according to the present invention promotes procollagen secretion, thereby increasing the amount of activated collagen, decreasing the expression of MMPs genes that catalyze collagen degradation, and increasing the expression of elastin genes. This can prevent or alleviate skin wrinkles and enhance skin elasticity.
  • the cosmetic composition of the present invention contains Cynconin as an active ingredient and with a dermatologically acceptable excipient, a basic cosmetic composition (washing agents such as cosmetics, creams, essences, cleansing foams and cleansing water, packs, body oils), color cosmetic compositions (Foundation, lipstick, mascara, makeup base), hair product composition (shampoo, rinse, hair conditioner, hair gel) and soap and the like.
  • a dermatologically acceptable excipient a basic cosmetic composition (washing agents such as cosmetics, creams, essences, cleansing foams and cleansing water, packs, body oils), color cosmetic compositions (Foundation, lipstick, mascara, makeup base), hair product composition (shampoo, rinse, hair conditioner, hair gel) and soap and the like.
  • the excipients include, but are not limited to, emollients, skin penetration enhancers, colorants, fragrances, emulsifiers, thickeners and solvents.
  • fragrances, pigments, fungicides, antioxidants, preservatives and moisturizing agents may be further included, and may include thickeners, inorganic salts, synthetic polymer materials and the like for the purpose of improving the properties.
  • it can be easily prepared by adding the above-mentioned sinconin to the normal face wash and the soap base.
  • the cream it may be prepared by adding cinnaconin or a salt thereof to a cream base of a general oil-in-water type (O / W).
  • synthetic or natural materials such as proteins, minerals, vitamins, etc.
  • for the purpose of improving physical properties such as flavors, chelating agents, pigments, antioxidants, and preservatives, may be added.
  • the content of cinconine contained in the cosmetic composition of the present invention is not limited thereto, but is preferably 0.001 to 10% by weight, more preferably 0.01 to 5% by weight based on the total weight of the composition. If the content is less than 0.001% by weight, the desired anti-aging or anti-wrinkle effect may not be expected, and if it is more than 10% by weight, there may be difficulties in safety or formulation preparation.
  • Health functional food composition for improving skin wrinkles or enhancing elasticity
  • the present invention provides a health functional food composition for improving skin wrinkles or enhancing elasticity, including cinchonine or a food acceptable salt thereof as an active ingredient. Specific details of the synonin are as described above.
  • the synonin when using the synonin as an additive of the health functional food, it may be added as it is or used with other foods or food ingredients, according to a conventional method It can be used properly.
  • the mixed amount of the active ingredient can be appropriately determined depending on the purpose of use, such as prevention, health or treatment.
  • Formulations of dietary supplements may be in the form of powders, granules, pills, tablets, capsules, as well as in the form of general foods or beverages.
  • the foodstuff which can add the said substance is a dairy product including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, ice cream, etc.
  • Various soups, beverages, teas, drinks, alcoholic beverages and vitamin complexes, etc. may include all foods in a conventional sense.
  • the ciconin in general, in the preparation of food or beverages, may be added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less based on 100 parts by weight of the raw material.
  • the amount in the case of long-term intake for health and hygiene or for health control, the amount may be below the above range, and the present invention has no problem in terms of safety in terms of using fractions from natural products. The above amount can also be used.
  • the beverage in the health functional food according to the present invention may contain various flavors or natural carbohydrates, etc. as an additional ingredient, as in general drinks.
  • the above-mentioned natural carbohydrates may be monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose and polysaccharides such as dextrin and cyclodextrin, sugar alcohols such as xylitol, sorbitol and erythritol.
  • sweetening agent natural sweetening agents such as tautin and stevia extract, synthetic sweetening agents such as saccharin and aspartame, and the like can be used.
  • the ratio of the natural carbohydrate may be about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 mL of the beverage according to the present invention.
  • the functional food for skin wrinkle improvement or elasticity enhancement is various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, pH adjusting agents. And stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks.
  • the composition for improving sleep of the present invention may contain fruit flesh for the production of natural fruit juice, fruit juice beverage and vegetable beverage. These components can be used independently or in combination. The ratio of such additives is not limited, but is generally selected from the range of 0.01 to 0.1 parts by weight relative to 100 parts by weight of the health functional food of the present invention.
  • the present invention provides a cosmetic composition for improving skin moisturizing, exfoliating, inhibiting erythema or improving skin photoaging, including cinchonine or a cosmetically acceptable salt thereof as an active ingredient. Specific details of the synonin are as described above.
  • the composition may increase the water content of the skin tissue, reduce the amount of water evaporation, promote skin moisturization, and suppress the erythema by reducing the erythema index.
  • the composition may improve skin photoaging by inhibiting the thickening of the skin epidermal layer and inhibiting the damage of the collagen fiber network of the skin epidermal-dermal junction.
  • the thickening of the skin epidermal layer by ultraviolet irradiation means that the skin damage due to photoaging is large.
  • the skin thickness was significantly increased by ultraviolet irradiation, and by ingesting an experimental diet containing cinnamon to the ultraviolet irradiated mouse, It was confirmed that the thickness was significantly reduced. That is, the cinconin according to the present invention can improve skin photoaging by reducing the thickness of the epidermal layer thickened by ultraviolet irradiation.
  • the dose of cinconin is preferably included at a concentration of 0.1 ⁇ M to 1000 ⁇ M, but is not limited thereto.
  • the cinnamon is less than the above concentration range, it is possible to suppress the increase in water content of the skin tissue and increase the amount of water evaporation, it is not possible to effectively suppress the thickening of the skin epidermal layer, the skin moisturizing, exfoliation, suppressing erythema or improving skin photoaging There is a problem that is difficult to achieve the effect of, and if the concentration range is exceeded, there may be concerns of toxicity including cytotoxicity.
  • the Cinconin according to the present invention effectively maintains moisture in skin tissue, reduces the erythema index, prevents thickening of the skin epidermal layer, promotes skin moisturization and exfoliation, and promotes erythema. It can suppress and improve skin photoaging.
  • the present invention provides a health functional food composition for improving skin moisturizing, removing dead skin cells, inhibiting erythema or improving skin photoaging, including cinchonine or a food acceptable salt thereof as an active ingredient. Specific details of the synonin are as described above.
  • Normal human dermal fibroblasts (neonatal foreskin) were purchased from ATCC (Manassas, VA, USA), and the cells were purchased using fibroblast growth medium (Promo Cell, Heidelberg) at 37 ° C., 5% CO 2. Cultures in incubators were used for the experiment.
  • mice Five-week-old male albino hairless mice (Skh-1) were purchased from Orient Bio (Gyeonggi-do, Korea) and subjected to a one week period of solid feed. Experimental animals were divided into 4 groups and 5 animals were assigned to each group and used for the experiment. Feed and water were freely ingested during the breeding period, and the temperature was maintained at 22 ⁇ 1 °C and humidity at 60 ⁇ 5%, and the photoperiod and dark cycle were adjusted to 12 hours daily.
  • Human skin fibroblasts of Preparation Example 1 were dispensed at 1.0 ⁇ 10 6 cells / well into 12 well-plates and added at a concentration of 100 ⁇ M of cinnamonine (CN) and incubated in a CO 2 incubator for 24 hours. After removing the medium of each well, washed once with PBS and again put 1 ml of PBS was irradiated with ultraviolet B (UVB) at 20 mJ / cm 2 conditions. PBS of each well was replaced with medium again and cultured for 24 hours, and then the amount of procollagen secreted into the medium was measured using a procollagen type IC-peptide EIA kit (Takara Bio, Japan). The standard solution included in the collagen measurement kit was diluted by concentration, and the absorbance was measured at 450 nm to prepare a standard concentration curve and calculate the amount of collagen produced.
  • UVB ultraviolet B
  • Example 2 The same procedure as in Example 1 was conducted except that 100 ⁇ M of vitamin C was treated.
  • Example 2 The same procedure as in Example 1 was conducted except that 100 ⁇ M of cinconine and 100 ⁇ M of vitamin C were treated.
  • the control cells irradiated with ultraviolet rays (+ UVB), procollagen secretion was significantly reduced compared to the normal cells (-UVB), in the case of Example 1, the control cells irradiated only with ultraviolet rays ( + UVB) significantly increased the amount of collagen by 24%.
  • the amount of collagen was increased by 47% compared to the UV irradiation control cells (+ UVB), which is higher than the amount of collagen observed in Comparative Example 1 or Example 1.
  • the cinconine according to the present invention has a similar effect to vitamin C known to act to stabilize and promote collagen.
  • the cinconin may increase the amount of activated collagen by promoting the secretion of procollagen.
  • UVB ultraviolet B
  • Example 3-1) The same procedure as in Example 2 was carried out except that a tablet diet was prepared according to the composition of AIN-93 rodent diet.
  • UVB ultraviolet B
  • Example 2 The same procedure as in Example 2 was conducted except that the diet prepared by adding 0.2% vitamin C (Sigma-Aldrich) to the AIN-93 tablet diet was supplied.
  • 0.2% vitamin C Sigma-Aldrich
  • Skins of Examples 2, Comparative Examples 3-1, and 4 mice subjected to UV irradiation for 10 weeks were made of silicone rubber to measure the extent of wrinkle formation. Attach a disk with a circular hole having a diameter of 1 cm to the back of the mouse, mix the reagent for making a replica plate, thinly spread it on the back of the hairless mouse, dry it completely, and carefully remove the disk to copy the disk. was produced. Fabrication temperature of the replica plate was carried out at a constant temperature and humidity condition of 20 ⁇ 23 °C, humidity 45 ⁇ 50%, and a silicon rubber impression material (Epigem, Seoul, Korea) for producing a replica plate. Analysis of the simulated platen was performed using a computer image analyzer (Visioline VL650, CK electronic GmbH, Germany) for total wrinkle area, maximum wrinkle depth, mean depth and mean wrinkles. Four wrinkle indicator items such as mean length were analyzed.
  • Example 2 Comparative Examples 3 and 4
  • the skin thickness of the mouse hip was measured using a digital micro caliper (Marathon Watch Company Ltd, Ontario, Canada).
  • the caliper used for the measurement was able to measure up to 0.01 mm and the adjustment function to apply a constant force to the thickness was able to measure the thickness of the skin under the same force.
  • Example 2 The dorsal skin tissue of Example 2, Comparative Examples 3 and 4 mice was extracted and fixed in 10% formalin. Subsequently, Hematoxylin and eosin (H & E) staining was performed by a Korean CFC (Gyeonggi-do, Korea) and observed using an optical microscope (IX71, Olympus, JPN) and photographed using a digital camera (DP71, Olympus, JPN). Photographed.
  • Korean CFC Korean CFC (Gyeonggi-do, Korea) and observed using an optical microscope (IX71, Olympus, JPN) and photographed using a digital camera (DP71, Olympus, JPN). Photographed.
  • the tissues were pulverized by adding 1 ml of Trizol solution per 0.1 g of dorsal skin tissue of Examples 2, Comparative Examples 3 and 4, and then centrifuged at 4 ° C. and 12,000 ⁇ g for 10 minutes. The supernatant was transferred to a new tube and 200 ⁇ l of chloroform was added and vortexed. After repeating this process twice, the supernatant was transferred to a new tube and isoprophanol and supernatant were added at a 1: 1 ratio. After shaking vigorously 10 times, the mixture was left at room temperature for 15 minutes, centrifuged at 12,000 ⁇ g and 4 ° C.
  • RNA samples were dissolved using nuclease free water.
  • a UV / VIS spectrophotometer (Beckman coulter, DU730) was measured the concentration of RNA samples extracted at 260 nm and 280 nm wavelength, and the integrity of the RNA samples were confirmed by agarose gel electrophoresis.
  • CDNA was synthesized by reverse transcription using oligo dT primer and superscript reverse transcriptase (GIBCO BRL, Gaithersburg, MD, USA) on RNA samples extracted from the back skin tissue. PCR was performed using 5D and 3 'flanking sequences of the gene cDNA to be amplified and templated cDNA obtained by reverse transcription, the primer sequence used is shown in Table 2 below. 1 ⁇ l of the amplified PCR product was electrophoresed on 1% agarose gel to confirm DNA band.
  • Comparative Example 3-1) elastin expression was significantly decreased in comparison with Comparative Example 3-2) which was not irradiated with ultraviolet rays, and in Example 2, Comparative Example 3-1 Elastin expression was not only significantly increased, compared to Comparative Example 4, it was confirmed that shows an excellent effect. That is, the synonin may exhibit an effect of promoting skin elasticity through promoting elastin expression.
  • the above ingredients were mixed and filled in an airtight cloth to prepare a powder.
  • tablets were prepared by tableting according to a conventional method for producing tablets.
  • the above components are dissolved in purified water according to a conventional preparation method, dissolved in purified water, and then lemon juice is added in an appropriate amount. After adjusting to 100 mL in total, sterilized and filled in a brown bottle to prepare a liquid formulation.
  • Formulation example 6 Preparation of dietary supplements
  • Vitamin B6 0.5 mg
  • composition ratio of the above-mentioned vitamin and mineral mixtures is mixed with a component suitable for a health food in a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method.
  • the granules may be prepared and used for preparing a health food composition according to a conventional method.
  • Formulation example 7 Manufacture of health drinks
  • composition ratio is mixed with a component suitable for a favorite beverage in a preferred embodiment, the composition ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and usage.
  • the compounding ratio is mixed with a component suitable for nutritional longevity in a preferred embodiment, the compounding ratio may be arbitrarily modified, and can be prepared according to a conventional manufacturing method in the cosmetic field.
  • the above blending ratio is mixed composition of a component suitable for a flexible softener in a preferred embodiment, but the blending ratio may be arbitrarily modified, it can be prepared according to the manufacturing method in the general cosmetic field.
  • the compounding ratio is mixed with a component suitable for nourishing cream in a preferred embodiment, the compounding ratio may be arbitrarily modified, and can be prepared according to a conventional manufacturing method in the cosmetic field.
  • the compounding ratio is mixed with a component suitable for a massage cream in a preferred embodiment, the compounding ratio may be arbitrarily modified, and can be prepared according to a manufacturing method in the general cosmetic field.
  • the compounding ratio is mixed with a component suitable for a pack in a preferred embodiment, the compounding ratio may be arbitrarily modified, and can be prepared according to a manufacturing method in the general cosmetic field.
  • the compounding ratio is mixed with a component suitable for a gel in a preferred embodiment, the compounding ratio may be arbitrarily modified, and can be prepared according to a conventional manufacturing method in the cosmetic field.
  • the blending ratio is a relatively suitable composition for the cosmetic composition in a preferred embodiment, but can be applied to cosmetics of various uses, including other color cosmetics, according to the efficacy that can be applied to a thin coating on the human body, that is, Ointment may be used for manufacturing, and the mixing ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and usage.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a cosmetic composition and a health functional food composition for reducing skin wrinkles, improving skin elasticity, promoting skin moisturizing, exfoliating skin, inhibiting erythema or reducing skin photoaging, the cosmetic composition and the health functional food composition containing cinchonine or a salt thereof as an active ingredient. More specifically, the cinchonine, according to the present invention, exhibits an effect of increasing the amount of procollagen secretion, promoting collagen biosynthesis, decreasing MMPs gene expression, increasing elastin gene expression, inhibiting erythema or inhibiting epidermal hyperplasia, and thus is effective in reducing skin wrinkles, improving skin elasticity, promoting skin moisturizing, exfoliating skin, inhibiting erythema or reducing skin photoaging.

Description

신코닌 또는 이의 염을 유효성분으로 함유하는 피부주름 개선, 보습, 탄력증진, 각질제거, 홍반억제 또는 피부광노화 개선용 조성물A composition for improving skin wrinkles, moisturizing, enhancing elasticity, exfoliating, inhibiting erythema or improving skin photoaging, containing cinnaconin or salts thereof as an active ingredient.
본 발명은 신코닌(Cinchonine) 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 주름 개선 또는 탄력 증진용 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition for improving skin wrinkles or enhancing elasticity comprising cinchonine or a cosmetically acceptable salt thereof as an active ingredient.
최근 의료기술의 발달로 평균수명이 연장되고 삶의 질 향상과 건강하고 아름다운 삶에 대한 욕구가 증가함에 따라 피부미용 및 건강에 대한 관심이 확대되고 있다. 이에 건강한 피부를 유지하고자 하는 목적에 따라 다양한 미용 기능성 화장품이 개발되었으며, 특히 피부 주름형성 예방, 완화와 개선을 위한 연구가 활발히 진행되고 있다. 아울러 최근 화장품의 성분이 피부진피에 도달하여 영양분을 공급하는데 한계가 있고, 식품으로 섭취하여 피부에 영양분 또는 기능성분을 공급하여 피부미용증진 효과를 나타낼 수 있다는 인식의 변화가 일어남에 따라 이너뷰티 식품소재들을 발굴하는 연구 또한 활발히 진행되고 있다(Chung, S. et al., γ-Linolenic acid in borage oil reverses epidermal hyperproliferation in guinea pigs. J Nutr, 132, 3090-3097, 2002; Tanno, O. et al., Nicotinamide increases biosynthesis of ceramides as well as other stratum corneum lipids to improve the epidermal permeability barrier. Br J Derm, 143, 524-531, 2000).Recently, as life expectancy is extended due to the development of medical technology and the quality of life and the desire for healthy and beautiful life are increasing, interest in skin beauty and health is expanding. Accordingly, various cosmetic functional cosmetics have been developed according to the purpose of maintaining healthy skin, and research for preventing, alleviating and improving skin wrinkle formation is being actively conducted. In addition, cosmetic ingredients have recently reached the skin dermis to supply nutrients, and as a result of the change in the perception that skin nutrients or functional ingredients can be ingested to improve skin beauty, resulting in inner beauty foods Excavations have also been actively conducted (Chung, S. et al., Γ-Linolenic acid in borage oil reverses epidermal hyperproliferation in guinea pigs.J Nutr, 132, 3090-3097, 2002; Tanno, O. et al. ., Nicotinamide increases biosynthesis of ceramides as well as other stratum corneum lipids to improve the epidermal permeability barrier.Br J Derm, 143, 524-531, 2000).
피부는 크게 표피(epidermis), 진피(dermis), 피하지방(hypodermis)의 세층으로 구성되어 있다, 표피, 특히 표피의 가장 외층인 각질층은 피부장벽의 역할을 함으로서 피부로부터 수분과 전해질 손실되는 것을 억제하는 한편, 진피층은 콜라겐과 엘라스틴 합성을 통하여 피부의 탄력을 유지하고 구조를 지지하는 역할을 한다. 즉, 콜라겐과 엘라스틴은 섬유아세포에서 생성되는 주요 단백질로서 피부의 기계적 견고성, 조직의 결합력 및 탄력성 등에 관여한다(Moskowit, R. W. et al, Role of collagen hydroiysate in bone and joint disease, Semin Arthritis Rheu, 30: 87, 2000). 콜라겐은 형태와 구조적 특징에 따라 다양한 isoform을 구성하며, 사람의 조직에서 총 28가지 콜라겐 isotype이 존재하는데, 이중 피부조직에 존재하는 콜라겐은 타입 1, 3. 4. 6. 7. 13, 14, 17 등이 알려져 있다. 콜라겐 타입 1과 3은 진피층의 세포간질 구성성분을 이루고, 콜라겐 타입 7은 표피와 진피를 연결부위(dermal and epidermal junction)의 주요 구성물질이 된다(Pei, M. et al., Expression of collagen type I, II and III in loose body of osteoarthitis, J. Orthop. Sci., 5: 288, 2000).The skin is composed of three layers: epidermis, dermis and hypodermis. The epidermis, especially the stratum corneum, which is the outermost layer of the epidermis, acts as a skin barrier, inhibiting the loss of water and electrolytes from the skin. Meanwhile, the dermal layer plays a role in maintaining the elasticity of the skin and supporting the structure through collagen and elastin synthesis. In other words, collagen and elastin are major proteins produced in fibroblasts and are involved in skin mechanical firmness, tissue cohesion and elasticity (Moskowit, RW et al, Role of collagen hydroiysate in bone and joint disease, Semin Arthritis Rheu, 30: 87, 2000). Collagen forms various isoforms according to the form and structural features, and there are 28 kinds of collagen isotypes in human tissues. Among them, collagen is present in types 1, 3. 4. 6. 7. 13, 14, 17 and the like are known. Collagen types 1 and 3 make up the interstitial components of the dermal layer, and collagen type 7 is the major component of the dermal and epidermal junctions (Pei, M. et al., Expression of collagen type) I, II and III in loose body of osteoarthitis, J. Orthop. Sci., 5: 288, 2000).
피부결합조직에는 세포외기질 단백질 중 타입 I 콜라겐이 가장 많은 양으로 존재하며, 그 밖에 엘라스틴, 피브로넥틴(fibronectin), 인테그린(integrin), 피브릴린(fibrillin), 프로테로글리칸 등의 단백질들이 존재한다. 새로이 합성된 프로콜라겐은 효소반응을 거쳐 피부세포의 세포외 공간으로 분비된 후 삼중나선구조(triple helix configuration)의 microfibril을 형성하고, microfibril들은 leucine-rich small proteoglycans과 결합하여 fibril을 형성한다. 결과적으로 이렇게 만들어진 fibril들이 모여 피부의 결합력과 탄력성을 제공하는 콜라겐 섬유를 형성하게 된다(Bateman, J.F. et al., Collagen superfamily. Extracellular matrix, Harwood, New York, 2, 22-26, 1996). Type I collagen is the largest amount of extracellular matrix protein in skin connective tissue, and other proteins such as elastin, fibronectin, integrin, fibrillin, and proteoglycan are present. do. The newly synthesized procollagen is secreted into the extracellular space of skin cells through an enzymatic reaction to form a microfibril of triple helix configuration, and the microfibrils combine with leucine-rich small proteoglycans to form fibrils. As a result, these fibrils gather to form collagen fibers that provide skin binding and elasticity (Bateman, J.F. et al., Collagen superfamily.Extracellular matrix, Harwood, New York, 2, 22-26, 1996).
피부노화는 피부 진피조직의 교원질 중 대부분을 차지하는 단백질인 콜라겐 함량이 감소하기 때문으로 알려져 있고, 콜라겐은 피부의 장력과 강도를 부여하기 때문에 콜라겐의 감소는 피부노화 및 주름생성과 매우 깊은 관계를 가지고 있다. 피부노화는 크게 생리학적 노화에 의한 내인성 노화, 그리고 지속적인 자외선(ultraviolet radiation, UV) 노출에 의해 일어나는 광노화로 구분된다. 반복적인 자외선 노출은 콜라겐 분해효소를 증가시키고 콜라겐 섬유의 변성 및 파괴를 유발하여 피부의 탄력을 감소시키고 주름의 생성을 촉진하는 결과를 초래한다. 즉, 지속적으로 자외선에 노출된 피부조직에는 활성산소종(ROS)의 발생이 증가하고, 후자는 epidermal growth factor receptor (EGF-R), tumor necrosis factor (TNF)-receptor 등에 의해 매개되는 신호전달체계를 통해 전염증성 사이토카인 생성을 촉진시키게 된다(Sachsenmaier, C. et al., Involvement of growth factor receptors in the mammalian UVC response. Cell, 78:963-972, 1994; Dy, L.C. et al., Augmentation of ultraviolet B radiation-induced tumor necrosis factor production by the epidermal platelet-activating factor receptor. J. Biol.Chem.: 274, 26917-2692, 1999), 이들 수용체의 활성화는 결과적으로 MAPK(mitogen-activated protein kinase)를 포함하는 downstream의 신호전달을 매개하는 단백질들을 활성화시키는 연속적인 인산화로 이루어지고, 결과적으로 activator protein-1(AP-1)과 nuclear factor κB(NF-κB)와 같은 전사인자를 활성화시켜 염증반응을 유발하고 matrix metalloproteinase(MMPs)와 같은 콜라겐 분해효소(collagenase)의 활성을 촉진시킴으로써 피부탄력을 감소시키고 주름생성을 촉진시키게 된다(Kang, S. et al., Inflammation and extracellular matrix degradation mediated by activated transcription factors nuclear factor-κB and activator protein-l in Inflammatory acne lesions in vivo. Am J. Pathol., 166: 1691-1699, 2005). AP-1은 세포의 성장과 분화에 관련되는 수많은 유전자의 발현을 조절하고 일부 MMPs의 발현을 강력히 조절한다. AP-1에 의해 발현이 조절되는 MMP 중 MMP-1은 collagenase 1으로 알려져 있으며, 타입 1과 3 콜라겐을 기질로 한다.Skin aging is known to decrease collagen content, a protein that accounts for most of the collagen of skin dermis. Collagen decreases the skin's tension and strength. have. Skin aging is largely divided into endogenous aging due to physiological aging and photoaging caused by continuous ultraviolet radiation (UV) exposure. Repeated ultraviolet exposure results in increased collagen degrading enzymes and causing denaturation and destruction of collagen fibers, reducing the elasticity of the skin and promoting the production of wrinkles. In other words, the generation of reactive oxygen species (ROS) increases continuously in skin tissues exposed to ultraviolet rays, and the latter is a signaling system mediated by epidermal growth factor receptor (EGF-R), tumor necrosis factor (TNF) -receptor, etc. Schsenmaier, C. et al., Involvement of growth factor receptors in the mammalian UVC response.Cell, 78: 963-972, 1994; Dy, LC et al., Augmentation of ultraviolet B radiation-induced tumor necrosis factor production by the epidermal platelet-activating factor receptor.J. Biol. Chem .: 274, 26917-2692, 1999), activation of these receptors results in mitogen-activated protein kinase (MAPK). It consists of a continuous phosphorylation that activates proteins that mediate downstream signaling, which in turn activates transcription factors such as activator protein-1 (AP-1) and nuclear factor κB (NF-κB). Induce matr By promoting the activity of collagenase, such as ix metalloproteinases (MMPs), skin elasticity is reduced and wrinkles are promoted (Kang, S. et al., Inflammation and extracellular matrix degradation mediated by activated transcription factors nuclear factor -κB and activator protein-l in Inflammatory acne lesions in vivo.Am J. Pathol., 166: 1691-1699, 2005). AP-1 regulates the expression of numerous genes involved in cell growth and differentiation and strongly regulates the expression of some MMPs. Among the MMPs whose expression is regulated by AP-1, MMP-1 is known as collagenase 1, and is based on type 1 and 3 collagen.
본 발명은 신코닌(Cinchonine) 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 주름 개선 또는 탄력 증진용 화장료 조성물 등을 제공하고자 한다. The present invention is to provide a cosmetic composition for improving skin wrinkles or enhancing elasticity, including Cinchonine (Cinchonine) or a cosmetically acceptable salt thereof as an active ingredient.
그러나, 본 발명이 이루고자 하는 기술적 과제는 이상에서 언급한 과제에 제한되지 않으며, 언급되지 않은 또 다른 과제들은 아래의 기재로부터 당업자에게 명확하게 이해될 수 있을 것이다.However, the technical problem to be achieved by the present invention is not limited to the above-mentioned problem, another task that is not mentioned will be clearly understood by those skilled in the art from the following description.
본 발명은 신코닌(Cinchonine) 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 주름 개선 또는 탄력 증진용 화장료 조성물을 제공한다. The present invention provides a cosmetic composition for improving skin wrinkles or enhancing elasticity comprising cinchonine or a cosmetically acceptable salt thereof as an active ingredient.
상기 신코닌은 i)프로콜라겐(procollagen) 분비량 증가, ii) 기질금속단백질 분해효소(matrixmetalloproteinase, MMP) 유전자 발현 감소, iii) ColⅠα1(collagen type alpha 1), ColⅠα2 또는 Col3α1 발현 증가 또는 iv) 엘라스틴(elastin) 유전자의 발현을 증가시킬 수 있다. The synonin is i) increased procollagen secretion, ii) decreased expression of matrix metalloproteinase (MMP) gene, iii) increased expression of collagen type alpha 1, ColIα2 or Col3α1 or iv) elastin ( elastin) may increase the expression of the gene.
상기 조성물은 비타민 C, 레티노산, TGF(transforming growth factor), 동물 태반 유래의 단백질, 베툴린산 및 클로렐라 추출물로 이루어진 군에서 선택되는 1 이상의 피부주름 개선 성분을 추가로 포함할 수 있다. The composition may further include at least one skin wrinkle improving component selected from the group consisting of vitamin C, retinoic acid, transforming growth factor (TGF), protein from animal placenta, betulinic acid and chlorella extract.
또한, 본 발명은 신코닌(Cinchonine) 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 보습 증진, 각질 제거, 홍반 억제 또는 피부광노화 개선용 화장료 조성물을 제공한다. The present invention also provides a cosmetic composition for improving skin moisturizing, exfoliating, inhibiting erythema or improving skin photoaging, including cinchonine or a cosmetically acceptable salt thereof as an active ingredient.
상기 조성물은 피부 표피층의 비후를 억제할 수 있다. The composition can inhibit thickening of the skin epidermal layer.
상기 조성물은 피부 표피-진피 결합부위의 교원섬유(collagen fiber)망의 손상을 억제할 수 있다. The composition can inhibit damage to the collagen fiber network of the skin epidermal-dermal bonds.
또한, 본 발명은 신코닌(Cinchonine) 또는 이의 식품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 주름 개선 또는 탄력 증진용 건강기능성 식품 조성물을 제공한다. In addition, the present invention provides a health functional food composition for improving skin wrinkles or enhancing elasticity comprising Cinchonine or a food acceptable salt thereof as an active ingredient.
또한, 본 발명은 신코닌(Cinchonine) 또는 이의 식품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 보습 증진, 각질 제거, 홍반 억제 또는 피부광노화 개선용 건강기능성 식품 조성물을 제공한다.The present invention also provides a health functional food composition for improving skin moisturizing, exfoliating, inhibiting erythema or improving skin photoaging, including cinchonine or a food acceptable salt thereof as an active ingredient.
또한, 본 발명은 신코닌(Cinchonine) 또는 이의 염을 유효성분으로 포함하는 조성물을 개체에 투여 또는 복용시키는 단계를 포함하는 피부 주름 개선, 탄력 증진, 피부 보습 증진, 각질 제거, 홍반 억제 또는 피부광노화 개선 방법을 제공한다.In addition, the present invention comprises the step of administering or taking a composition comprising Cinchonine (Cinchonine) or a salt thereof as an active ingredient to the subject to improve skin wrinkles, enhance elasticity, enhance skin moisturization, exfoliation, inhibit erythema or skin photoaging Provide ways to improve.
또한, 본 발명은 신코닌(Cinchonine) 또는 이의 염을 유효성분으로 포함하는 조성물의 피부 주름 개선, 탄력 증진, 피부 보습 증진, 각질 제거, 홍반 억제 또는 피부광노화 개선 용도를 제공한다.The present invention also provides a skin wrinkle improvement, elasticity enhancement, skin moisturization enhancement, exfoliation, erythema suppression or skin photoaging improvement of a composition comprising Cinchonine (Cinchonine) or a salt thereof as an active ingredient.
본 발명은 신코닌(Cinchonine) 또는 이의 염을 유효성분으로 포함하는 피부 주름 개선, 탄력 증진, 피부 보습 증진, 각질 제거, 홍반 억제 또는 피부 광노화 개선용 조성물에 관한 것으로, 상기 신코닌은 피부섬유아세포에서 프로콜라겐의 분비를 촉진시킴에 따라, 활성화된 콜라겐의 양을 증가시키고, 피부 진피층에서 교원섬유(collagen fiber)의 양을 증가시키며 콜라겐의 분해를 촉매하는 MMPs 유전자 발현을 억제할 수 있는 바, 피부 주름 개선 또는 탄력 증진에 이용될 수 있다. The present invention relates to a composition for improving skin wrinkles, enhancing elasticity, enhancing skin moisturizing, removing dead skin cells, inhibiting erythema or improving skin photoaging, including cinchonine or a salt thereof as an active ingredient, wherein the cinchonine is a fibroblast cell Promoting the secretion of procollagen in, it can increase the amount of activated collagen, increase the amount of collagen fibers in the dermal layer and inhibit the expression of MMPs genes that catalyze the breakdown of collagen, It can be used to improve skin wrinkles or to improve elasticity.
또한, 상기 신코닌은 피부 조직의 수분함유량을 증가시키고 수분증발량은 감소시키는 바, 피부 보습 개선 효과가 있으며, 홍반을 억제할 수 있고, 비후해진 피부 표피층의 두께를 감소시킬 수 있는 바, 각질 제거 또는 자외선 등에 의한 피부 광노화를 방지할 수 있다. In addition, the cinconin increases the water content of the skin tissue and decreases the water evaporation amount, the skin moisturizing improvement effect, can suppress the erythema, can reduce the thickness of the thickened skin epidermal layer, exfoliation Or skin photoaging by ultraviolet rays etc. can be prevented.
도 1은 사람의 피부섬유아세포에서 프로콜라겐의 분비량을 측정한 결과를 나타내는 것이다. Figure 1 shows the result of measuring the amount of procollagen secretion in human skin fibroblasts.
도 2는 실시예 2, 비교예 3 및 4에 따라 제조된 실험식이를 섭취한 마우스의 체중증가량 및 식이 섭취량을 측정한 결과를 나타내는 것이다. Figure 2 shows the results of measuring the weight gain and dietary intake of the mice ingested the experimental diet prepared according to Example 2, Comparative Examples 3 and 4.
도 3은 실시예 2, 비교예 3 및 4에 따라 제조된 실험식이를 섭취한 마우스 피부조직의 수분량, 탄력성 및 홍반 지수를 측정한 결과를 나타내는 것이다. Figure 3 shows the results of measuring the moisture content, elasticity and erythema index of the mouse skin tissue ingested experimental diet prepared according to Example 2, Comparative Examples 3 and 4.
도 4는 실시예 2, 비교예 3 및 4에 따라 제조된 실험식이를 섭취한 마우스의 등 피부조직을 나타내는 사진이다. Figure 4 is a photograph showing the back skin tissue of the mouse taking the experimental diet prepared in Example 2, Comparative Examples 3 and 4.
도 5는 실시예 2, 비교예 3 및 4에 따라 제조된 실험식이를 섭취한 마우스 등 피부조직의 주름형성 정도를 측정한 결과를 나타내는 것이다. Figure 5 shows the results of measuring the degree of wrinkles of the skin tissue, such as the mouse taking the experimental diet prepared according to Example 2, Comparative Examples 3 and 4.
도 6은 실시예 2, 비교예 3 및 4에 따라 제조된 실험식이를 섭취한 마우스의 피부두께를 측정한 결과를 나타내는 것이다. Figure 6 shows the results of measuring the skin thickness of the mouse taking the experimental diet prepared in Example 2, Comparative Examples 3 and 4.
도 7은 실시예 2, 비교예 3 및 4에 따라 제조된 실험식이를 섭취한 마우스의 교원섬유(collagen fiber) 양 및 형태 변화를 나타내는 것이다. Figure 7 shows the collagen fiber (collagen fiber) amount and morphological changes of mice fed the experimental diet prepared according to Example 2, Comparative Examples 3 and 4.
도 8은 본 발명에 따른 신코닌(Cinchonine)을 처리한 무모 마우스의 등 조직에서 콜라겐 및 MMPs 유전자의 발현 변화를 나타내는 것이다. Figure 8 shows the expression changes of collagen and MMPs genes in the back tissue of hairless mice treated with Cinchonine according to the present invention.
도 9는 본 발명에 따른 신코닌(Cinchonine)을 처리한 무모 마우스의 등 조직에서 엘라스틴(Elastin) 유전자의 발현 변화를 나타내는 것이다.Figure 9 shows the expression change of the elastin (Elastin) gene in the back tissue of the hairless mouse treated with Cinchonine according to the present invention.
본 발명자들은 신코닌이 피부섬유아세포에서 프로콜라겐의 분비를 촉진하고, 피부 진피층에서 교원섬유의 양을 증가시키며, MMPs 유전자의 발현 억제하고, 피부 조직에서 수분함유를 촉진 및 수분 증발을 억제함으로써, 피부 주름 개선, 탄력 증진, 피부 보습 증진에 효과가 있음을 확인하였고, 홍반 지수 감소 및 비후해진 피부 표피층의 두께를 감소하여 홍반 억제 및 각질 제거, 피부 광노화 개선에 효과가 있음을 확인함으로써, 본 발명을 완성하였다. The present inventors have found that by synonin promotes secretion of procollagen in dermal fibroblasts, increases the amount of collagen fibers in the dermal dermal layer, inhibits the expression of MMPs genes, promotes water content in skin tissues and inhibits water evaporation, The present invention has been found to be effective in improving skin wrinkles, enhancing elasticity and enhancing skin moisturization, and reducing the erythema index and reducing the thickness of the thickened skin epidermal layer, thereby making it effective in inhibiting erythema and removing dead skin cells and improving skin photoaging. Was completed.
본 명세서 내 "피부 주름 개선"은 피부의 주름 및 탄력과 관련된 능력을 유지 또는 강화시키는 것을 의미한다. 피부 진피층의 교원섬유인 콜라겐(collagen)과 탄력섬유인 엘라스틴(elastin)이 그러한 역할을 하는 주요 단백질로서 피부 탄력을 주관하는데, 콜라겐의 생합성은 피부의 내, 외적 영향을 받게 된다. 구체적으로, 피부세포는 자연 노화로 인하여 세포 활성이 감소되면 콜라겐 섬유의 감소가 일어나거나, 또는 외적 요인으로서 자외선의 과량 조사되거나 스트레스 등에 의해 생성된 활성 산소가 단백질의 티올기(thiol: -SH)와 반응하여 효소 활성을 저해하거나, 콜라겐, 엘라스틴 등의 분해 효소의 발현을 증가시켜 피부의 주름을 증가시키고 탄력을 감소시켜 피부 노화가 진행된다.As used herein, "skin improvement" refers to maintaining or enhancing the capacity associated with wrinkles and elasticity of the skin. Collagen (collagen) and elastic fiber elastin (collagen) in the dermal layer of the skin is the main protein that plays a role in the skin elasticity, collagen biosynthesis is affected by the internal and external skin. Specifically, the skin cells are reduced in cell activity due to natural aging, the collagen fibers are reduced, or the active oxygen generated by excessive irradiation of ultraviolet rays or stress as an external factor is the thiol group of the protein (thiol: -SH) In response to inhibiting the enzyme activity or by increasing the expression of degradation enzymes, such as collagen, elastin, increase the wrinkles of the skin and decrease the elasticity, the skin aging progresses.
본 명세서 내 "피부광노화"는 일광노출(자외선)에 의해 피부가 노화되는 생리현상을 의미하는 것으로서, 장기간 동안 태양(자외선)에 노출되면, 얼굴, 목에 깊은 주름을 증가시키고 또 피부의 건조 및 피부 표면이 거칠어지거나 반점, 주근깨 등의 색소침착을 일으킨다. As used herein, "skin light aging" refers to a physiological phenomenon in which the skin ages due to sun exposure (ultraviolet rays), and when exposed to the sun (ultraviolet rays) for a long period of time, deep wrinkles on the face and neck, and drying and The surface of the skin becomes rough or causes pigmentation such as spots and freckles.
피부 주름 개선 또는 탄력 증진용 For improving skin wrinkles or enhancing elasticity 화장료Cosmetics 조성물 Composition
본 발명은 신코닌(Cinchonine) 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 주름 개선 또는 탄력 증진용 화장료 조성물을 제공한다. The present invention provides a cosmetic composition for improving skin wrinkles or enhancing elasticity comprising cinchonine or a cosmetically acceptable salt thereof as an active ingredient.
구체적으로, 상기 신코닌은 키나나무(Cinchona), 키니네(Cinchona officinalis), 키나수 느룹나무(Cinchona pubescens), 올리브(Olea europaea) 및 청미래덩굴(Smilax china) 등의 식물에 함유되어 있는 알칼로이드(alkaloid)계 화합물로서, 구조식은 C19H22N20이고, 분자량은 294.4 g/mol이며, 하기 화학식 1로 표시될 수 있다. Specifically, the cinnacon is an alkaloid contained in a plant such as Cinchona, Cinona officinalis, Cinchona pubescens, Olive (Olea europaea), and Smilax china. As a) -based compound, the structural formula is C 19 H 22 N 20 , the molecular weight is 294.4 g / mol, it may be represented by the formula (1).
또한, 상기 신코닌과 동일한 효능을 갖는 범위 내에서 신코닌 수화물, 신코닌 유도체 등을 포함할 수 있고, 이의 용매 화합물이나 입체 이성질체 또한 포함할 수 있다.  In addition, within the range having the same efficacy as the above-mentioned shinconin, it may include a sinconin hydrate, a sinconin derivative, and the like, and may also include a solvent compound or stereoisomer thereof.
[화학식 1][Formula 1]
Figure PCTKR2018003866-appb-I000001
Figure PCTKR2018003866-appb-I000001
상기 신코닌의 수득방법은 특별히 한정되지 않으며, 상기 신코닌을 함유하고 있는 식물로부터 분리하거나, 공지된 제법을 사용하여 화학적으로 합성하거나 또는 시판되는 것을 사용할 수 있다.There is no particular limitation on the method for obtaining cinnacon, and it is possible to use a compound which is isolated from the plant containing the cinnaconin, chemically synthesized using a known manufacturing method, or commercially available.
상기 신코닌은 i)프로콜라겐(procollagen) 분비량 증가, ii) 기질금속단백질 분해효소(matrixmetalloproteinase, MMP) 유전자 발현 감소, iii) ColⅠα1(collagen type alpha 1), ColⅠα2 또는 Col3α1 발현 증가 또는 iv) 엘라스틴(elastin) 유전자의 발현을 증가시킬 수 있다. The synonin is i) increased procollagen secretion, ii) decreased expression of matrix metalloproteinase (MMP) gene, iii) increased expression of collagen type alpha 1, ColIα2 or Col3α1 or iv) elastin ( elastin) may increase the expression of the gene.
구체적으로, 피부를 구성하는 주 단백질인 콜라겐은 피부진피에 존재하는 섬유아세포에서 프로콜라겐의 형태로 합성된 후 세포외 기질로 분비되는데, 세포외 기질로 분비된 프로콜라겐은 세포표면에 존재하는 procollagen peptidase에 의해 C-말단이 분해되고 활성형 콜라겐으로 전환되므로 C-peptide 함량을 측정하면 활성화된 콜라겐 함량을 측정할 수 있다. 즉, 본 발명에 따른 신코닌은 피부섬유아세포에서 프로콜라겐을 합성을 촉진함으로써, 활성화된 콜라겐의 양을 증가시킬 수 있다. Specifically, collagen, a major protein constituting the skin, is synthesized in the form of procollagen in fibroblasts present in the dermis and then secreted into the extracellular matrix. The procollagen secreted into the extracellular matrix is present on the cell surface. Since the C-terminus is decomposed by peptidase and converted into active collagen, the activated collagen content can be determined by measuring the C-peptide content. In other words, according to the present invention, the synonin may promote synthesis of procollagen in dermal fibroblasts, thereby increasing the amount of activated collagen.
또한, 콜라겐 분해를 촉매하는 기질금속단백질 분해효소(matrixmetalloproteinase, MMP)는 포유류에서 23개의 타입이 존재하며 이중 자외선에 의해 증가하는 MMP 타입은 1, 3 및 9번으로 알려져 있고 이들 세가지 타입의 MMPs는 콜라겐 타입 1과 3을 분해하는 효소이다. 구체적으로, MMP-1의 경우, 콜라겐 섬유의 중간을 절단하며 MMP-3 및 MMP-9는 상기 절단된 콜라겐 섬유를 세분해서 절단하는 역할을 한다. 즉, 본 발명에 따른 신코닌은 MMPs 유전자의 발현을 유의적으로 감소시킴으로써, 콜라겐 섬유의 분해를 억제할 수 있으며, 피부조직에서 콜라겐 단백질의 합성을 증가시킴에 따라, 주름 형성을 억제할 수 있다. In addition, there are 23 types of matrix metalloproteinases (MMPs) that catalyze collagen degradation, and MMP types known to increase by UV rays are known as Nos. 1, 3 and 9, and these three types of MMPs It is an enzyme that breaks down collagen types 1 and 3. Specifically, in the case of MMP-1, the middle of the collagen fibers are cut and MMP-3 and MMP-9 serve to cut and cut the cut collagen fibers. In other words, the cinconin according to the present invention can significantly inhibit the expression of the MMPs gene, thereby inhibiting the degradation of collagen fibers, and by increasing the synthesis of collagen protein in skin tissue, can inhibit wrinkle formation. .
피부의 진피는 교원섬유인 콜라겐과 탄력섬유인 엘라스틴으로 구성되어 있다. 상기 콜라겐 섬유는 피부 장력 형성과 구조적인 통합을 이루게 하고, 엘라스틴 섬유는 피부 탄력에 관여함으로써 피부 탄력을 증진시킬 수 있다. 구체적으로, 본 발명에 따른 신코닌은 엘라스틴 발현을 촉진함으로써, 피부 탄력 증진 효과를 나타낸다. The dermis of the skin is composed of collagen (collagen fiber) and elastin (elastic fiber). The collagen fibers allow structural integration with skin tension formation, and elastin fibers can enhance skin elasticity by engaging in skin elasticity. Specifically, the syntholin according to the present invention promotes elastin expression, thereby exhibiting skin elasticity enhancing effect.
더 나아가, 본 발명에 따른 조성물은 비타민 C, 레티노산, TGF(transforming growth factor), 동물 태반 유래의 단백질, 베툴린산 및 클로렐라 추출물로 이루어진 군에서 선택되는 1 이상의 피부주름 개선 성분을 추가로 포함할 수 있으며, 비타민 C인 것이 바람직하나, 이에 한정되지 않는다. 구체적으로, 본 발명의 일 실시예에 따르면, 신코닌 및 비타민 C를 피부 섬유아세포에 함께 처리하는 경우, 프로콜라겐의 분비가 상기 신코닌 또는 비타민 C를 단독으로 처리하는 경우와 비교하여 20p% 내지 23p% 증가하였음을 확인할 수 있으며, 콜비 공식에 의해 현저한 상승 효과를 입증하였다. 즉, 신코닌은 비타민 C와 함께 사용하는 경우, 단독으로 사용하는 경우에 비하여 피부섬유아세포에서 프로콜라겐의 분비가 증가함에 따라 활성화된 콜라겐의 양을 효과적으로 증가시킬 수 있다. Furthermore, the composition according to the present invention may further include at least one skin wrinkle improving component selected from the group consisting of vitamin C, retinoic acid, transforming growth factor (TGF), protein from animal placenta, betulinic acid and chlorella extract. It may be, but is preferably vitamin C, but is not limited thereto. Specifically, according to one embodiment of the present invention, when synthesizing the skin fibroblasts with the synonin and vitamin C, the secretion of procollagen 20p% to when compared to the case of the single treatment with the neoconsin or vitamin C alone It can be seen that the 23p% increase, a significant synergistic effect was proved by Colby's formula. In other words, when used together with vitamin C, Cinconin can effectively increase the amount of activated collagen as the secretion of procollagen increases in dermal fibroblasts compared to the case of using it alone.
상기 신코닌의 용량은 0.1 μM 내지 1000 μM의 농도로 포함되는 것이 바람직하나, 이에 한정되지 않는다. 이때, 신코닌이 상기 농도 범위 미만인 경우, 프로콜라겐 합성 및 콜라겐 분해를 촉매하는 MMPs 유전자 발현의 억제가 저하되어, 피부 주름 개선 또는 탄력 증진의 효과를 발휘하기 어려운 문제점이 있고, 상기 농도 범위를 초과하는 경우, 세포독성을 포함한 독성의 우려사항이 있을 수 있다. The dose of cinconin is preferably included at a concentration of 0.1 μM to 1000 μM, but is not limited thereto. At this time, when the cinnaconin is less than the concentration range, the inhibition of MMPs gene expression catalyzing procollagen synthesis and collagen degradation is reduced, there is a problem that it is difficult to exert the effect of skin wrinkle improvement or elasticity enhancement, exceeding the concentration range If so, there may be toxicity concerns, including cytotoxicity.
상기한 바와 같이, 본 발명에 따른 신코닌은 프로콜라겐 분비를 촉진함으로써, 활성화된 콜라겐의 양을 증가시키고, 콜라겐 분해를 촉매하는 MMPs 유전자의 발현을 감소시키며, 엘라스틴 유전자의 발현을 증가시킴에 따라, 피부 주름을 예방하거나 완화할 수 있으며, 피부 탄력을 증진시킬 수 있다. As described above, the Cinconin according to the present invention promotes procollagen secretion, thereby increasing the amount of activated collagen, decreasing the expression of MMPs genes that catalyze collagen degradation, and increasing the expression of elastin genes. This can prevent or alleviate skin wrinkles and enhance skin elasticity.
본 발명의 화장료 조성물은 신코닌을 유효성분으로 함유하며 피부학적으로 허용 가능한 부형제와 함께 기초 화장품 조성물(화장수, 크림, 에센스, 클렌징 폼 및 클렌징 워터와 같은 세안제, 팩, 보디오일), 색조 화장품 조성물(화운데이션, 립스틱, 마스카라, 메이크업 베이스), 두발 제품 조성물(샴푸, 린스, 헤어컨디셔너, 헤어젤) 및 비누 등의 형태로 제조될 수 있다.The cosmetic composition of the present invention contains Cynconin as an active ingredient and with a dermatologically acceptable excipient, a basic cosmetic composition (washing agents such as cosmetics, creams, essences, cleansing foams and cleansing water, packs, body oils), color cosmetic compositions (Foundation, lipstick, mascara, makeup base), hair product composition (shampoo, rinse, hair conditioner, hair gel) and soap and the like.
상기 부형제로는 이에 한정되지는 않으나 예를 들어, 피부연화제, 피부 침투 증강제, 착색제, 방향제, 유화제, 농화제 및 용매를 포함할 수 있다. 또한, 향료, 색소, 살균제, 산화방지제, 방부제 및 보습제 등을 추가로 포함할 수 있으며, 물성개선을 목적으로 점증제, 무기염류, 합성 고분자 물질 등을 포함할 수 있다. 예를 들면, 본 발명의 화장료 조성물로 세안제 및 비누를 제조하는 경우에는 통상의 세안제 및 비누 베이스에 상기 신코닌을 첨가하여 용이하게 제조할 수 있다. 크림을 제조하는 경우에는 일반적인 수중유적형(O/W)의 크림베이스에 신코닌 또는 이의 염을 첨가하여 제조할 수 있다. 여기에 향료, 킬레이트제, 색소, 산화방지제, 방부제 등과 물성개선을 목적으로 한 단백질, 미네랄, 비타민 등 합성 또는 천연소재를 추가로 첨가할 수 있다. 본 발명의 화장료 조성물에 함유되는 신코닌의 함량은 이에 한정되지 않지만 전체 조성물 총중량에 대하여 0.001 내지 10 중량%인 것이 바람직하고, 0.01 내지 5 중량%인 것이 더욱 바람직하다. 상기 함량이 0.001중량% 미만에서는 목적하는 항노화 또는 주름개선 효과를 기대할 수 없고, 10 중량% 초과에서는 안전성 또는 제형상의 제조에 어려움이 있을 수 있다.The excipients include, but are not limited to, emollients, skin penetration enhancers, colorants, fragrances, emulsifiers, thickeners and solvents. In addition, fragrances, pigments, fungicides, antioxidants, preservatives and moisturizing agents may be further included, and may include thickeners, inorganic salts, synthetic polymer materials and the like for the purpose of improving the properties. For example, in the case of preparing the face wash and the soap with the cosmetic composition of the present invention, it can be easily prepared by adding the above-mentioned sinconin to the normal face wash and the soap base. In the case of preparing the cream, it may be prepared by adding cinnaconin or a salt thereof to a cream base of a general oil-in-water type (O / W). To this, synthetic or natural materials, such as proteins, minerals, vitamins, etc., for the purpose of improving physical properties, such as flavors, chelating agents, pigments, antioxidants, and preservatives, may be added. The content of cinconine contained in the cosmetic composition of the present invention is not limited thereto, but is preferably 0.001 to 10% by weight, more preferably 0.01 to 5% by weight based on the total weight of the composition. If the content is less than 0.001% by weight, the desired anti-aging or anti-wrinkle effect may not be expected, and if it is more than 10% by weight, there may be difficulties in safety or formulation preparation.
피부 주름 개선 또는 탄력 증진용 건강기능성 식품 조성물Health functional food composition for improving skin wrinkles or enhancing elasticity
본 발명은 신코닌(Cinchonine) 또는 이의 식품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 주름 개선 또는 탄력 증진용 건강기능성 식품 조성물을 제공한다. 상기 신코닌의 구체적인 내용은 전술한 바와 같다. The present invention provides a health functional food composition for improving skin wrinkles or enhancing elasticity, including cinchonine or a food acceptable salt thereof as an active ingredient. Specific details of the synonin are as described above.
본 발명에 따른 피부 주름 개선 또는 탄력 증진용 건강기능식품에 있어서, 상기 신코닌을 건강기능식품의 첨가물로 사용하는 경우 이를 그대로 첨가하거나 다른 식품 또는 식품성분과 함께 사용할 수 있고, 통상적인 방법에 따라 적절하게 사용할 수 있다. 유효 성분의 혼합양은 예방, 건강 또는 치료 등의 각 사용 목적에 따라 적합하게 결정할 수 있다.In the health functional food for skin wrinkle improvement or elasticity enhancement according to the present invention, when using the synonin as an additive of the health functional food, it may be added as it is or used with other foods or food ingredients, according to a conventional method It can be used properly. The mixed amount of the active ingredient can be appropriately determined depending on the purpose of use, such as prevention, health or treatment.
건강기능식품의 제형은 산제, 과립제, 환, 정제, 캡슐제의 형태뿐만 아니라 일반 식품 또는 음료의 형태 어느 것이나 가능하다.Formulations of dietary supplements may be in the form of powders, granules, pills, tablets, capsules, as well as in the form of general foods or beverages.
상기 식품의 종류에는 특별히 제한은 없고, 상기 물질을 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 쵸콜렛, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알콜 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 식품을 모두 포함할 수 있다.There is no restriction | limiting in particular in the kind of said food, The foodstuff which can add the said substance is a dairy product including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, ice cream, etc. , Various soups, beverages, teas, drinks, alcoholic beverages and vitamin complexes, etc., may include all foods in a conventional sense.
일반적으로, 식품 또는 음료의 제조시에 상기 신코닌은 원료 100 중량부에 대하여 15 중량부 이하, 바람직하게는 10 중량부 이하의 양으로 첨가할 수 있다. 그러나, 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하일 수 있으며, 또한 본 발명은 천연물로부터의 분획물을 이용하는 점에서 안전성 면에서 문제가 없으므로 상기 범위 이상의 양으로도 사용할 수 있다.In general, in the preparation of food or beverages, the ciconin may be added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less based on 100 parts by weight of the raw material. However, in the case of long-term intake for health and hygiene or for health control, the amount may be below the above range, and the present invention has no problem in terms of safety in terms of using fractions from natural products. The above amount can also be used.
본 발명에 따른 건강기능식품 중 음료는 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로 함유할 수 있다. 상술한 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토스, 슈크로스와 같은 디사카라이드 및 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드, 자일리톨, 소르비톨, 에리트리톨 등의 당알콜일 수 있다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명에 따른 음료 100 mL당 약 0.01 ~ 0.04 g, 바람직하게는 약 0.02 ~ 0.03 g일 수 있다.The beverage in the health functional food according to the present invention may contain various flavors or natural carbohydrates, etc. as an additional ingredient, as in general drinks. The above-mentioned natural carbohydrates may be monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose and polysaccharides such as dextrin and cyclodextrin, sugar alcohols such as xylitol, sorbitol and erythritol. As the sweetening agent, natural sweetening agents such as tautin and stevia extract, synthetic sweetening agents such as saccharin and aspartame, and the like can be used. The ratio of the natural carbohydrate may be about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 mL of the beverage according to the present invention.
상기 외에 본 발명에 따른 피부 주름 개선 또는 탄력 증진용 건강기능식품은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제를 함유할 수 있다. 그 밖에 본 발명의 수면 개선용 조성물은 천연 과일쥬스, 과일쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 혼합하여 사용할 수 있다. 이러한 첨가제의 비율은 제한되지 않으나 본 발명의 건강기능식품 100 중량부 대비 0.01 ~ 0.1 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the functional food for skin wrinkle improvement or elasticity enhancement according to the present invention is various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, pH adjusting agents. And stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks. In addition, the composition for improving sleep of the present invention may contain fruit flesh for the production of natural fruit juice, fruit juice beverage and vegetable beverage. These components can be used independently or in combination. The ratio of such additives is not limited, but is generally selected from the range of 0.01 to 0.1 parts by weight relative to 100 parts by weight of the health functional food of the present invention.
피부 보습 증진, 각질 제거, 홍반 억제 또는 Enhance skin moisturizing, exfoliate, suppress erythema or 피부광노화Skin photoaging 개선용  Improvement 화장료Cosmetics 조성물 Composition
본 발명은 신코닌(Cinchonine) 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 보습 증진, 각질 제거, 홍반 억제 또는 피부광노화 개선용 화장료 조성물을 제공한다. 상기 신코닌의 구체적인 내용은 전술한 바와 같다. The present invention provides a cosmetic composition for improving skin moisturizing, exfoliating, inhibiting erythema or improving skin photoaging, including cinchonine or a cosmetically acceptable salt thereof as an active ingredient. Specific details of the synonin are as described above.
구체적으로, 상기 조성물은 피부조직의 수분함유량을 증가시키고, 수분증발량을 감소시킴으로써, 피부 보습을 증진시킬 수 있으며, 홍반 지수를 감소시킴으로써 홍반을 억제할 수 있다. Specifically, the composition may increase the water content of the skin tissue, reduce the amount of water evaporation, promote skin moisturization, and suppress the erythema by reducing the erythema index.
또한, 상기 조성물은 피부 표피층의 비후를 억제하고, 피부 표피-진피 결합부위의 교원섬유(collagen fiber)망의 손상을 억제함으로써 피부광노화를 개선할 수 있다. 구체적으로, 자외선 등에 의한 광노화가 진행되면 피부 진피층을 보호하기 위해 각질층의 형성이 증가하여 피부가 두꺼워진다. 따라서 자외선 조사에 의해 피부 표피층의 두께가 두꺼워졌다는 것은 광노화에 의한 피부손상이 크다는 것을 의미한다. 본 발명의 일 실시예에 따르면, 자외선을 조사한 마우스의 피부두께 변화를 확인한 결과, 자외선 조사에 의해 피부두께가 유의하게 증가하였고, 상기 자외선 조사한 마우스에 신코닌이 포함된 실험식이를 섭취시킴으로써, 피부두께가 유의하게 감소하였음을 확인할 수 있었다. 즉, 본 발명에 따른 신코닌은 자외선 조사에 의해 비후해진 표피층의 두께를 감소시킴으로써, 피부광노화를 개선할 수 있다. In addition, the composition may improve skin photoaging by inhibiting the thickening of the skin epidermal layer and inhibiting the damage of the collagen fiber network of the skin epidermal-dermal junction. Specifically, when photoaging by ultraviolet rays or the like proceeds, the formation of the stratum corneum increases to protect the dermal layer of the skin, resulting in thickening of the skin. Therefore, the thickening of the skin epidermal layer by ultraviolet irradiation means that the skin damage due to photoaging is large. According to one embodiment of the present invention, as a result of confirming the change in the skin thickness of the mouse irradiated with ultraviolet rays, the skin thickness was significantly increased by ultraviolet irradiation, and by ingesting an experimental diet containing cinnamon to the ultraviolet irradiated mouse, It was confirmed that the thickness was significantly reduced. That is, the cinconin according to the present invention can improve skin photoaging by reducing the thickness of the epidermal layer thickened by ultraviolet irradiation.
상기 신코닌의 용량은 0.1 μM 내지 1000 μM의 농도로 포함되는 것이 바람직하나, 이에 한정되지 않는다. 이때, 신코닌이 상기 농도 범위 미만인 경우, 피부조직의 수분함유량 증가를 억제하고 수분증발량을 증가시키며, 피부 표피층의 비후를 효과적으로 억제할 수 없는 바, 피부 보습, 각질 제거, 홍반 억제 또는 피부광노화 개선의 효과를 발휘하기 어려운 문제점이 있고, 상기 농도 범위를 초과하는 경우, 세포독성을 포함한 독성의 우려사항이 있을 수 있다. The dose of cinconin is preferably included at a concentration of 0.1 μM to 1000 μM, but is not limited thereto. At this time, when the cinnamon is less than the above concentration range, it is possible to suppress the increase in water content of the skin tissue and increase the amount of water evaporation, it is not possible to effectively suppress the thickening of the skin epidermal layer, the skin moisturizing, exfoliation, suppressing erythema or improving skin photoaging There is a problem that is difficult to achieve the effect of, and if the concentration range is exceeded, there may be concerns of toxicity including cytotoxicity.
상기한 바와 같이, 본 발명에 따른 신코닌은 피부 조직 내 수분을 효과적으로 유지하고, 홍반 지수를 감소시키며, 피부 표피층의 두께가 비후해지는 것을 방지함으로써, 피부 보습 증진 및각질 제거를 촉진하고, 홍반을 억제하며 피부광노화를 개선시킬 수 있다. As described above, the Cinconin according to the present invention effectively maintains moisture in skin tissue, reduces the erythema index, prevents thickening of the skin epidermal layer, promotes skin moisturization and exfoliation, and promotes erythema. It can suppress and improve skin photoaging.
피부 보습 증진, 각질 제거, 홍반 억제 또는 Enhance skin moisturizing, exfoliate, suppress erythema or 피부광노화Skin photoaging 개선용 건강기능성 식품 조성물 Health functional food composition for improvement
본 발명은 신코닌(Cinchonine) 또는 이의 식품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 보습 증진, 각질 제거, 홍반 억제 또는 피부광노화 개선용 건강기능성 식품 조성물을 제공한다. 상기 신코닌의 구체적인 내용은 전술한 바와 같다. The present invention provides a health functional food composition for improving skin moisturizing, removing dead skin cells, inhibiting erythema or improving skin photoaging, including cinchonine or a food acceptable salt thereof as an active ingredient. Specific details of the synonin are as described above.
이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예를 제시한다. 그러나 하기의 실시예는 본 발명을 보다 쉽게 이해하기 위하여 제공되는 것일 뿐, 하기 실시예에 의해 본 발명의 내용이 한정되는 것은 아니다.Hereinafter, preferred examples are provided to aid in understanding the present invention. However, the following examples are merely provided to more easily understand the present invention, and the contents of the present invention are not limited by the following examples.
[[ 준비예Preparation ]]
준비예Preparation 1. One.
사람피부섬유아세포(normal human dermal fibroblasts, neonatal foreskin)를 ATCC사(Manassas, VA, USA)로부터 구매하였고, 구입한 세포를 fibroblast growth medium(Promo Cell, Heidelberg)을 이용하여 37℃, 5% CO2 인큐베이터에서 배양하여 실험에 사용하였다.Normal human dermal fibroblasts (neonatal foreskin) were purchased from ATCC (Manassas, VA, USA), and the cells were purchased using fibroblast growth medium (Promo Cell, Heidelberg) at 37 ° C., 5% CO 2. Cultures in incubators were used for the experiment.
준비예 Preparation 2. 2.
5주령 수컷 알비노 무모 생쥐(Skh-1)를 오리엔트바이오(Gyeonggi-do, Korea)에서 구입하여 고형사료로 1주일간 적응기간을 거쳤다. 실험동물은 4개 군으로 분류하여 군별로 5 마리씩 배정하여 실험에 사용하였다. 사육 기간 동안 사료와 물을 자유로이 섭취하도록 하였으며, 온도는 22 ± 1℃, 습도는 60 ± 5%로 유지하고 매일 광주기와 암주기가 12시간이 되도록 조절하였다. Five-week-old male albino hairless mice (Skh-1) were purchased from Orient Bio (Gyeonggi-do, Korea) and subjected to a one week period of solid feed. Experimental animals were divided into 4 groups and 5 animals were assigned to each group and used for the experiment. Feed and water were freely ingested during the breeding period, and the temperature was maintained at 22 ± 1 ℃ and humidity at 60 ± 5%, and the photoperiod and dark cycle were adjusted to 12 hours daily.
[[ 실시예Example ] ]
실시예Example 1.  One. ProcollagenProcollagen Type I C-peptide(PIP) 농도 측정 Type I C-peptide (PIP) Concentration
준비예 1의 사람피부섬유아세포를 12 well-plate에 1.0×106 cells/well 씩 분주하여 신코닌(CN) 100 μM의 농도로 첨가하여 24시간동안 CO2 배양기에서 배양하였다. 각 well의 배지를 제거한 후 PBS로 1회 세척하고 다시 1 ml의 PBS를 넣은 후 20 mJ/cm2 조건으로 ultraviolet B(UVB)를 조사하였다. 각 well의 PBS를 다시 배지로 교체하여 24시간동안 배양한 후, procollagen type ⅠC-peptide EIA kit(Takara Bio, Japan)를 이용하여 배지로 분비된 프로콜라겐 양을 측정하였다. 콜라겐 측정 키트에 포함된 표준용액을 농도별로 희석하고 450 nm에서 흡광도를 측정하여 표준농도 곡선을 작성하고 콜라겐 생성량을 산정하였다.Human skin fibroblasts of Preparation Example 1 were dispensed at 1.0 × 10 6 cells / well into 12 well-plates and added at a concentration of 100 μM of cinnamonine (CN) and incubated in a CO 2 incubator for 24 hours. After removing the medium of each well, washed once with PBS and again put 1 ml of PBS was irradiated with ultraviolet B (UVB) at 20 mJ / cm 2 conditions. PBS of each well was replaced with medium again and cultured for 24 hours, and then the amount of procollagen secreted into the medium was measured using a procollagen type IC-peptide EIA kit (Takara Bio, Japan). The standard solution included in the collagen measurement kit was diluted by concentration, and the absorbance was measured at 450 nm to prepare a standard concentration curve and calculate the amount of collagen produced.
비교예Comparative example 1. One.
비타민 C 100 μM 을 처리하였다는 점을 제외하고는 상기 실시예 1과 동일한 방법으로 수행하였다. The same procedure as in Example 1 was conducted except that 100 μM of vitamin C was treated.
비교예Comparative example 2. 2.
신코닌 100 μM 및 비타민 C 100 μM 을 처리하였다는 점을 제외하고는 상기 실시예 1과 동일한 방법으로 수행하였다. The same procedure as in Example 1 was conducted except that 100 μM of cinconine and 100 μM of vitamin C were treated.
그 결과, 도 1에 나타난 바와 같이, 자외선을 조사한 대조세포(+UVB)의 경우, 정상세포(-UVB)에 비해 프로콜라겐 분비량이 현저히 감소하였고, 실시예 1의 경우, 자외선만 조사한 대조세포(+UVB)에 비해 콜라겐 양이 24% 유의하게 증가하였다. 또한, 비교예 2의 경우, 자외선 조사 대조세포(+UVB)에 비해 콜라겐 양이 47% 유의하게 증가하였고, 이는 비교예 1 또는 실시예 1에서 관찰된 콜라겐 양보다 더 높은 수치이다. 즉, 본 발명에 따른 신코닌은 콜라겐을 안정시키고 촉진하는 등의 작용을 하는 것으로 알려진 비타민 C와 유사한 효과가 있다. 또한, 상기 신코닌을 비타민 C와 함께 사용할 경우, 프로콜라겐의 분비를 촉진함에 따라, 활성화된 콜라겐의 양을 증가시킬 수 있다.As a result, as shown in Figure 1, the control cells irradiated with ultraviolet rays (+ UVB), procollagen secretion was significantly reduced compared to the normal cells (-UVB), in the case of Example 1, the control cells irradiated only with ultraviolet rays ( + UVB) significantly increased the amount of collagen by 24%. In addition, in Comparative Example 2, the amount of collagen was increased by 47% compared to the UV irradiation control cells (+ UVB), which is higher than the amount of collagen observed in Comparative Example 1 or Example 1. In other words, the cinconine according to the present invention has a similar effect to vitamin C known to act to stabilize and promote collagen. In addition, when used with vitamin C, the cinconin may increase the amount of activated collagen by promoting the secretion of procollagen.
실시예Example 2.  2. 신코닌이Neoconin 첨가된  Added 정제식이Tablet diet 섭취 Intake
준비예 2의 마우스에 AIN-93 rodent diet 구성(Reeves, PG et al., J Nutr, 123:1939-1951, 1993)에 준하여 조제된 정제식이에 0.2% Cinchonine (Sigma-Aldrich)를 첨가하여 제조된 식이를 10주간, 매일 오전 10~11시 사이 물과 함께 공급하였으며, 상기 AIN-93 rodent diet의 조성을 하기 표 1에 나타냈다. Prepared by adding 0.2% Cinchonine (Sigma-Aldrich) to the tablets prepared according to AIN-93 rodent diet composition (Reeves, PG et al., J Nutr, 123: 1939-1951, 1993) to the mouse of Preparation Example 2 The prepared diet was supplied with water between 10 and 11 am daily for 10 weeks, and the composition of the AIN-93 rodent diet is shown in Table 1 below.
실험사육기간 동안 무모생쥐의 등 부분에 ultraviolet B (UVB)를 주 3회 조사하였으며 자외선 조사량은 처음 1주 동안은 100 mJ/cm2, 2주째는 200 mJ/cm2, 3주부터 10주까지는 300 mJ/cm2로 조사하였다. 사육하는 동안 매주 체중 및 피부두께를 측정하였고, 등 피부 부위의 사진촬영을 실시하였다. During the breeding period, ultraviolet B (UVB) was irradiated to the back of the hairless mice three times a week. The UV irradiation dose was 100 mJ / cm 2 for the first week, 200 mJ / cm 2 for the second week, and from 3 to 10 weeks. The irradiation was at 300 mJ / cm 2 . During breeding, body weight and skin thickness were measured every week, and photographs of the back skin were taken.
실험사육 마지막 날 실험동물을 6시간 공복시키고 마취한 상태에서 혈액과 등 피부조직을 채취하였다. 혈액시료는 주사기로 복부 하대정맥에서 채취하여 EDTA가 코팅된 튜브에 담고 2,000×g에서 15분간 원심분리한 후 혈장을 분리하여 분석 시까지 -70℃에서 냉동보관하였다. 등 피부조직의 일부는 즉시 -70℃ 냉동고에 보관한 후 분자생물학적 검사에 사용하였고, 일부는 10% 포르말린 용액에 고정하여 면역조직화학적 염색에 사용하였다.On the last day of the experiment, the animals were fasted for 6 hours and blood and back skin tissues were collected under anesthesia. Blood samples were collected from the abdominal inferior vena cava with a syringe, centrifuged at 2,000 × g for 15 minutes, and plasma was separated and stored frozen at −70 ° C. until analysis. Some of the back skin tissues were immediately stored in the -70 ℃ freezer and used for molecular biological tests, and some were fixed in 10% formalin solution and used for immunohistochemical staining.
비교예Comparative example 3. 3.
3-1) AIN-93 rodent diet 구성에 준하여 조제된 정제식이를 공급하였다는 점을 제외하고는 상기 실시예 2와 동일한 방법으로 수행하였다. 3-1) The same procedure as in Example 2 was carried out except that a tablet diet was prepared according to the composition of AIN-93 rodent diet.
3-2) ultraviolet B (UVB)를 조사하지 않았다는 점을 제외하고는 상기 비교예 3-1)과 동일한 방법으로 수행하였다. 3-2) The same procedure as in Comparative Example 3-1) was conducted except that ultraviolet B (UVB) was not irradiated.
비교예Comparative example 4. 4.
AIN-93 정제식이에 0.2% 비타민 C(Sigma-Aldrich)를 첨가하여 제조된 식이를 공급하였다는 점을 제외하고는 상기 실시예 2와 동일한 방법으로 수행하였다. The same procedure as in Example 2 was conducted except that the diet prepared by adding 0.2% vitamin C (Sigma-Aldrich) to the AIN-93 tablet diet was supplied.
성분ingredient AIN-AIN- 93G식이93G diet (g/kg diet)(g / kg diet) 신코닌Shinkonin 보충식이Supplementary diet (CN)(CN) (g/kg diet)(g / kg diet) 비타민C 보충식이(VitC)Vitamin C Supplement (VitC) (g/kg diet)(g / kg diet)
카제인 Casein 200200 200200 200200
말토덱스트린Maltodextrin 132132 132132 132132
옥수수 전분Corn starch 397.486397.486 395.486395.486 395.486395.486
수크로오스 Sucrose 100100 100100 100100
셀룰로오스 cellulose 5050 5050 5050
콩기름 Soybean oil 7070 7070 7070
비타민 복합물 Vitamin complex 1010 1010 1010
미네랄 복합물 Mineral complex 3535 3535 3535
콜린 비타르트레이트Choline Bitartrate 2.52.5 2.52.5 2.52.5
L-시스틴L-cystine 33 33 33
Tert-부티하이드로퀴논Tert-Butyhydroquinone 0.0140.014 0.0140.014 0.0140.014
CinchonineCinchonine -- 22 --
Vitamin CVitamin c -- -- 22
총합(g)Total (g) 1,0001,000 1,0001,000 1,0001,000
실험예Experimental Example 1. 무모 생쥐의 체중 및 식이 섭취량 변화 1. Changes in Body Weight and Dietary Intake in Hairless Mice
상기 실시예 2, 비교예 3 및 4 마우스의 체중 및 식이 섭취량을 매주 측정하였다. 그 결과, 도 2에 나타난 바와 같이, 신코닌 및 비타민 C 섭취는 상기 마우스의 체중 및 십이 섭취량에 유의한 영향을 미치지 않음을 확인할 수 있었다. Body weight and dietary intake of the above Example 2, Comparative Examples 3 and 4 mice were measured weekly. As a result, as shown in Figure 2, it was confirmed that the intake of cinnaconin and vitamin C did not significantly affect the weight and twelve intake of the mouse.
실험예Experimental Example 2. 피부 보습, 탄력성 및  2. Moisturizing skin, elasticity and 홍반지수Erythema index 측정 Measure
상기 실시예 2, 비교예 3 및 4의 마우스에 대하여 Corneometer®, Tewameter®, Cutometer®, Mexameter® (CK Electronics GmbH)을 이용하여 피부 수분함유량, 수분증발량, 탄력성 및 홍반지수를 실험 종료일에 1회 측정하였다. 측정 시 실험동물 등의 일정한 부분을 가볍게 눌러서 나타나는 수치를 기록하였다.Corn moisture, water evaporation, elasticity and erythema index using the Corneometer®, Tewameter®, Cutometer®, Mexameter® (CK Electronics GmbH) for the mice of Examples 2, Comparative Examples 3 and 4 once at the end of the experiment Measured. When measuring, the numerical value that appears by lightly pressing a certain part of the experimental animal and the like was recorded.
그 결과, 도 3에 나타난 바와 같이, 10주 동안 자외선을 조사받은 비교예 3-1)의 경우, 자외선을 조사받지 않은 비교예 3-2)의 경우와 비교하여, 피부조직의 수분함유랑 및 탄력성은 유의하게 감소한 한편, 수분증발량 및 홍반지수는 유의하게 증가함을 확인할 수 있었다. 또한, 실시예 2의 경우, 같은 세기의 UV가 조사되었음에도 불구하고 비교예 3-1)에 비해 수분함유랑 및 탄력성은 각기 225% 및 82% 유의하게 증가하였고, 수분증발량 및 홍반지수는 각각 55% 및 40% 유의하게 감소하였음을 확인할 수 있었다.As a result, as shown in Figure 3, in the case of Comparative Example 3-1) irradiated with ultraviolet rays for 10 weeks, compared with the case of Comparative Example 3-2) not irradiated with ultraviolet rays, the moisture content of the skin tissue and Elasticity was significantly decreased, while water evaporation and erythema index were significantly increased. In addition, in the case of Example 2, the moisture content and elasticity significantly increased 225% and 82%, respectively, compared to Comparative Example 3-1) despite the same intensity of UV irradiation, moisture evaporation and erythema index 55 respectively It was confirmed that the% and 40% significantly decreased.
실험예Experimental Example 3. 등 피부조직의 주름 측정 3. Wrinkle measurement of back skin tissue
10주 동안 자외선 조사를 실시한 실시예 2, 비교예 3-1 및 4 마우스의 피부를 실리콘 고무로 모사판을 제작하여 주름의 형성 정도를 측정하였다. 상기 마우스의 등 부분에 지름이 1 cm가 되는 원모양의 구멍이 있는 디스크를 부착하고 모사판 제작용 시약을 혼합하여 무모 생쥐의 등 부분에 얇게 펴 바르고 완전히 말린 다음 디스크를 조심스럽게 떼어내어 모사판을 제작하였다. 모사판의 제작 온도는 20 ~ 23 ℃, 습도 45 ~ 50%의 항온항습 상태에서 실시하였으며, 모사판 제작용 실리판 고무 인상재(Epigem, Seoul, Korea)를 사용하였다. 제작한 모사판의 분석은 컴퓨터 영상분석기(Visioline VL650, CK electronic GmbH, Germany)을 사용하여 주름의 총면적(total wrinkle area), 최대 주름깊이(max wrinkle depth), 주름 평균깊이(mean depth) 및 평균길이(mean length) 등의 4가지 주름지표 항목을 분석하였다.Skins of Examples 2, Comparative Examples 3-1, and 4 mice subjected to UV irradiation for 10 weeks were made of silicone rubber to measure the extent of wrinkle formation. Attach a disk with a circular hole having a diameter of 1 cm to the back of the mouse, mix the reagent for making a replica plate, thinly spread it on the back of the hairless mouse, dry it completely, and carefully remove the disk to copy the disk. Was produced. Fabrication temperature of the replica plate was carried out at a constant temperature and humidity condition of 20 ~ 23 ℃, humidity 45 ~ 50%, and a silicon rubber impression material (Epigem, Seoul, Korea) for producing a replica plate. Analysis of the simulated platen was performed using a computer image analyzer (Visioline VL650, CK electronic GmbH, Germany) for total wrinkle area, maximum wrinkle depth, mean depth and mean wrinkles. Four wrinkle indicator items such as mean length were analyzed.
그 결과, 도 4에 나타난 바와 같이, 비교예 3-1)의 경우, 자외선을 조사받지 않은 비교예 3-2)에 비해 굵고 깊게 패인 주름과 함께 잔주름이 형성된 것을 관찰할 수 있었으며, 실시예 2의 경우, 같은 세기의 UV가 조사되었음에도 불구하고 상기 비교예 3-1)의 경우에 비해 깊은 주름이 거의 사라지는 등, 주름의 굵기와 깊이가 현저히 개선된 것을 확인할 수 있었다. 또한, 도 5에 나타난 바와 같이, 컴퓨터 영상분석기를 이용하여 모사판에서 주름형성 정도를 수치화 한 결과에서도 실시예 2의 경우 비교예 3-1)의 경우에 비해 총 주름면적, 평균 주름깊이, 최대 주름깊이 및 평균 주름길이가 각각 53%, 33%, 43% 및 59%로 유의하게 감소하였고, 이와 같은 신코닌의 주름개선 효능은 비타민 C에서 관찰된 주름개선효능과 유사하거나 더 좋음을 확인할 수 있었다. 즉, 신코닌의 섭취는 자외선조사에 의한 주름생성을 현저히 억제하는 효과가 있음을 알 수 있다.As a result, as shown in Figure 4, in Comparative Example 3-1), compared to Comparative Example 3-2) not irradiated with ultraviolet light, it was observed that the fine wrinkles were formed along with the deep wrinkles wrinkles, Example 2 In case of irradiating UV of the same intensity, it was confirmed that the thickness and depth of the wrinkles were remarkably improved compared to the case of Comparative Example 3-1). In addition, as shown in Fig. 5, the total wrinkle area, average wrinkle depth, maximum in the case of Example 2 compared to the case of Comparative Example 3-1) in the result of quantifying the degree of wrinkle formation in the replica plate using a computer image analyzer Wrinkle depth and mean wrinkle length were significantly reduced to 53%, 33%, 43% and 59%, respectively, and the antiwrinkle efficacy of Cinconin was similar to or better than that observed in vitamin C. there was. In other words, it can be seen that the intake of synconin has an effect of significantly inhibiting wrinkle formation by ultraviolet irradiation.
실험예Experimental Example 4. 피부두께 변화 4. Skin thickness change
(1) 등 피부두께 변화 측정(1) back skin thickness measurement
상기 실시예 2, 비교예 3 및 4 마우스 엉덩이 부분의 피부두께를 디지털 마이크로 캘리퍼(Marathon Watch Company Ltd, Ontario, Canada)를 이용하여 측정하였다. 측정할 때 사용된 캘리퍼는 0.01 mm까지 측정 가능하며 두께에 일정한 힘을 가할 수 있는 조절기능을 갖추고 있어 같은 힘을 준 상태에서 피부의 두께 측정이 가능하였다.Example 2, Comparative Examples 3 and 4 The skin thickness of the mouse hip was measured using a digital micro caliper (Marathon Watch Company Ltd, Ontario, Canada). The caliper used for the measurement was able to measure up to 0.01 mm and the adjustment function to apply a constant force to the thickness was able to measure the thickness of the skin under the same force.
그 결과, 도 6a에 나타난 바와 같이, 비교예 3-1)의 경우, 자외선을 조사받지 않은 비교예 3-2)의 경우와 비교하여, 피부두께가 유의하게 증가하였고 실시예 2의 경우, 비교예 3-1)에 비해 피부두께가 14% 유의하게 감소하였음을 확인할 수 있었다. As a result, as shown in Figure 6a, in the case of Comparative Example 3-1), compared with the case of Comparative Example 3-2) not irradiated with ultraviolet rays, the skin thickness was significantly increased and in the case of Example 2, the comparison Compared to Example 3-1, it was confirmed that the skin thickness was significantly reduced by 14%.
(2) 피부조직의 면역조직화학적 염색(2) immunohistochemical staining of skin tissue
상기 실시예 2, 비교예 3 및 4 마우스의 등 피부 조직을 적출하고 10% 포르말린에 고정하였다. 이후, 한국 CFC (경기도, 한국)에 의뢰하여 Hematoxylin and eosin(H&E) 염색을 한 뒤 광학현미경 (IX71, Olympus, JPN)을 이용하여 관찰하고, digital camera (DP71, Olympus, JPN)를 이용하여 사진을 촬영하였다.The dorsal skin tissue of Example 2, Comparative Examples 3 and 4 mice was extracted and fixed in 10% formalin. Subsequently, Hematoxylin and eosin (H & E) staining was performed by a Korean CFC (Gyeonggi-do, Korea) and observed using an optical microscope (IX71, Olympus, JPN) and photographed using a digital camera (DP71, Olympus, JPN). Photographed.
그 결과, 도 6b에 나타나 바와 같이, 비교예 3-1)의 경우, 자외선을 조사받지 않은 비교예 3-2) 에 비해 피부 표피층이 비후해진 것이 관찰되었고, 실시예 2의 경우 자외선 조사에 의해 비후해진 표피층의 두께가 현저히 감소되었음을 확인할 수 있었다. As a result, as shown in Fig. 6B, in Comparative Example 3-1), it was observed that the skin epidermal layer was thickened in comparison with Comparative Example 3-2) which was not irradiated with ultraviolet rays, and in Example 2 by ultraviolet irradiation It was confirmed that the thickness of the thickened epidermal layer was significantly reduced.
실험예Experimental Example 5. 진피층 내 교원섬유(collagen fiber)의 양 및 형태 변화 5. Changes in the amount and shape of collagen fibers in the dermis
Masson's trichrome(M&T) 염색을 하였다는 점을 제외하고는 상기 실험예 4-(2)와 동일한 방법으로 수행하였다. Except for Masson's trichrome (M & T) staining was carried out in the same manner as in Experimental Example 4- (2).
그 결과, 도 7에 나타난 바와 같이, 비교예 3-2)의 경우, 표피 밑의 진피층에서 aniline blue에 강하게 염색된 교원섬유가 관찰되었으나, 비교예 3-1)의 경우, 교원섬유가 aniline blue에 의해 미약하게 염색됨을 확인할 수 있었다. 또한, 실시예 2의 경우, 비교예 3-1)과 비교하여, 진피층에서 교원섬유의 밀도가 상대적으로 조밀하고 배열이 규칙적이었으며, aniline blue에 의한 염색정도도 더 강하여 비교예 3-2)에 가까운 양상을 보임을 확인할 수 있었다.As a result, as shown in FIG. 7, in Comparative Example 3-2), collagen fibers strongly stained with aniline blue were observed in the dermal layer under the epidermis, but in Comparative Example 3-1), the collagen fibers were aniline blue. It was confirmed that the dye is weakly. In addition, in Example 2, compared to Comparative Example 3-1), the density of collagen fibers in the dermal layer was relatively dense and the arrangement was regular, and staining by aniline blue was also stronger. It was confirmed that there was a close pattern.
실험예Experimental Example 6. 마우스 피부조직의 유전자 발현 변화 6. Gene Expression Changes in Mouse Skin Tissues
상기 실시예 2, 비교예 3 및 4 마우스의 등 피부조직 0.1 g 당 Trizol 용액 1 ml을 첨가하여 조직을 분쇄한 후, 4℃, 12,000 × g에서 10분간 원심분리 하였다. 상층액을 새 튜브로 옮긴 후 chloroform 200 ㎕을 첨가하고, vortex하였다. 이 과정을 두 번 반복한 다음, 상층액을 새 튜브로 옮긴 후 isoprophanol과 상층액을 1:1 비율로 첨가하였다. 10회 세게 흔든 다음 실온에서 15분 동안 방치한 후, 12,000 × g, 4℃에서 10분간 원심분리 시킨 후 상층액을 제거하고, 남은 침전물에 70% ethanol 1 ml을 가한 후 7,500 × g, 4℃에서 5분 동안 원심분리 하였다. 이후, 에탄올을 제거하고 RNA 침전물이 담긴 튜브를 실온에서 15분 동안 건조시킨 후, nuclease free water를 사용하여 RNA pellet을 용해시켰다. UV/VIS spectrophotometer(Beckman coulter, DU730)를 이용하여 260 nm 및 280 nm 파장에서 추출된 RNA 시료의 농도를 측정하고, agarose gel electrophoresis를 실시하여 RNA 시료의 integrity를 확인하였다.The tissues were pulverized by adding 1 ml of Trizol solution per 0.1 g of dorsal skin tissue of Examples 2, Comparative Examples 3 and 4, and then centrifuged at 4 ° C. and 12,000 × g for 10 minutes. The supernatant was transferred to a new tube and 200 μl of chloroform was added and vortexed. After repeating this process twice, the supernatant was transferred to a new tube and isoprophanol and supernatant were added at a 1: 1 ratio. After shaking vigorously 10 times, the mixture was left at room temperature for 15 minutes, centrifuged at 12,000 × g and 4 ° C. for 10 minutes, and then the supernatant was removed, and 1 ml of 70% ethanol was added to the remaining precipitate, followed by 7,500 × g and 4 ° C. Centrifuge for 5 minutes at. Thereafter, ethanol was removed and the tube containing the RNA precipitate was dried at room temperature for 15 minutes, and then the RNA pellet was dissolved using nuclease free water. Using a UV / VIS spectrophotometer (Beckman coulter, DU730) was measured the concentration of RNA samples extracted at 260 nm and 280 nm wavelength, and the integrity of the RNA samples were confirmed by agarose gel electrophoresis.
등 피부조직에서 추출된 RNA 시료를 대상으로 oligo dT primer와 superscript reverse transcriptase (GIBCO BRL, Gaithersburg, MD, USA)을 이용하여 reverse transcription을 수행함으로써 cDNA를 합성하였다. Reverse transcription을 통해 얻은 cDNA를 template로 하고 증폭하고자 하는 유전자 cDNA의 5'과 3' flanking sequence를 primer로 사용하여 PCR을 수행하였으며, 이때 사용된 primer sequence를 하기 표 2에 나타냈다. 증폭된 PCR 산물 1 ㎕를 1% agarose gel에 전기영동 하여 DNA band를 확인하였다.CDNA was synthesized by reverse transcription using oligo dT primer and superscript reverse transcriptase (GIBCO BRL, Gaithersburg, MD, USA) on RNA samples extracted from the back skin tissue. PCR was performed using 5D and 3 'flanking sequences of the gene cDNA to be amplified and templated cDNA obtained by reverse transcription, the primer sequence used is shown in Table 2 below. 1 μl of the amplified PCR product was electrophoresed on 1% agarose gel to confirm DNA band.
Gene descriptionGene description PrimersPrimers Sequences (5'→3')Sequences (5 '→ 3') AnnealingAnnealing temperaturetemperature (℃)(℃) PCRPCR product product (bp)(bp)
Collagen type Ⅰ alpha 1 (Col1α1)Collagen type Ⅰ alpha 1 (Col1α1) F F ggcaacagtcgcttcacctaggcaacagtcgcttcaccta 5555 164164
RR agtccgaattcctggtctggagtccgaattcctggtctgg
Collagen type Ⅰ alpha 2 (Col1α2)Collagen type Ⅰ alpha 2 (Col1α2) F F cggttctgttggtcctgttgcggttctgttggtcctgttg 5555 103103
RR acccctgtgccctttatcacacccctgtgccctttatcac
Collagen type Ⅲ alpha 1 (Col3α1)Collagen type III alpha 1 (Col3α1) F F taaccaaggctgcaagatggtaaccaaggctgcaagatgg 5555 104104
RR accagtgcttacgtgggaca accagtgcttacgtgggaca
Matrix metallopeptidase 1a (MMP-1a)Matrix metallopeptidase 1a (MMP-1a) F F ccctgtgtttcacaacggagccctgtgtttcacaacggag 5555 133133
RR cctcagcttttcagccatca cctcagcttttcagccatca
Matrix metallopeptidase 1b (MMP-1b)Matrix metallopeptidase 1b (MMP-1b) F F tttgctcatgcttttctgcctttgctcatgcttttctgcc 5555 146146
RR gaatgggagagtccaagggagaatgggagagtccaaggga
Matrix metallopeptidase 3 (MMP-3)Matrix metallopeptidase 3 (MMP-3) F F tgctggtatggagcttctgctgctggtatggagcttctgc 5555 142142
RR catctccaacccgaggaactcatctccaacccgaggaact
Matrix metallopeptidase 9 (MMP-9)Matrix metallopeptidase 9 (MMP-9) F F gtggaccatgaggtgaaccagtggaccatgaggtgaacca 5555 102102
RR actgcacggttgaagcaaagactgcacggttgaagcaaag
ElastinElastin FF tagggtgcaaagggttgtgttagggtgcaaagggttgtgt 6060 193193
RR ccaaagagcacaccaacaatcaccaaagagcacaccaacaatca
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) F F ggagattgttgccatcaacgggagattgttgccatcaacg 5555 122122
RR tgacaagcttcccattctcgtgacaagcttcccattctcg
그 결과, 도 8에 나타난 바와 같이, 비교예 3-1)의 경우, 비교예 3-2)의 경우와 비교하여 피부조직의 콜라겐 타입 1α1, 1α2, 및 콜라겐 타입 3α1의 발현은 유의하게 감소하였고, MMP-1a 및 -1b, MMP-3, 그리고 MMP-9 유전자 발현은 유의하게 증가함을 확인할 수 있었다. 한편, 실시예 2의 경우, 비교예 3-1)의 경우와 비교하여 콜라겐 타입 1α1, 1α2, 및 콜라겐 타입 3α1의 발현은 유의하게 증가하였고, MMP-1a, MMP-1b, MMP-3, 및 MMP-9 유전자 발현은 유의하게 감소함을 확인할 수 있었다. 즉, 신코닌은 피부조직의 콜라겐 단백질 합성을 증가시키고 콜라겐 섬유의 분해를 저해함으로써 자외선조사에 의한 주름형성을 억제할 수 있다. As a result, as shown in FIG. 8, in the case of Comparative Example 3-1), the expression of collagen type 1α1, 1α2, and collagen type 3α1 of the skin tissue was significantly decreased compared to that of Comparative Example 3-2). , MMP-1a and -1b, MMP-3, and MMP-9 gene expression was significantly increased. On the other hand, in the case of Example 2, the expression of collagen type 1α1, 1α2, and collagen type 3α1 were significantly increased as compared with that of Comparative Example 3-1), and MMP-1a, MMP-1b, MMP-3, and MMP-9 gene expression was found to be significantly reduced. That is, cinconin can inhibit the formation of wrinkles by ultraviolet irradiation by increasing collagen protein synthesis of skin tissues and inhibiting the degradation of collagen fibers.
또한, 도 9에 나타난 바와 같이, 비교예 3-1)의 경우, 자외선을 조사받지 않은 비교예 3-2)에 비해 엘라스틴 발현이 유의하게 감소하였고, 실시예 2의 경우, 비교예 3-1)에 비해 엘라스틴 발현이 유의하게 증가하였을 뿐만 아니라, 비교예 4와 비교하였을 때도, 뛰어난 효과를 나타냄을 확인할 수 있었다. 즉, 신코닌은 엘라스틴 발현 촉진을 통해 피부 탄력 증진 효과를 나타낼 수 있다. In addition, as shown in FIG. 9, in Comparative Example 3-1), elastin expression was significantly decreased in comparison with Comparative Example 3-2) which was not irradiated with ultraviolet rays, and in Example 2, Comparative Example 3-1 Elastin expression was not only significantly increased, compared to Comparative Example 4, it was confirmed that shows an excellent effect. That is, the synonin may exhibit an effect of promoting skin elasticity through promoting elastin expression.
하기에 본 발명의 화합물을 함유하는 조성물의 제제예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Hereinafter, the preparation examples of the composition containing the compound of the present invention will be described, but the present invention is not intended to limit the present invention but only to explain in detail.
제제예Formulation example 1:  One: 산제의Powder 제조 Produce
신코닌 20 ㎎ Cinconine 20 mg
유당수화물 100 ㎎ Lactose Carb 100 mg
탈크 10 ㎎ Talc 10 mg
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조하였다.The above ingredients were mixed and filled in an airtight cloth to prepare a powder.
제제예Formulation example 2: 정제의 제조 2: preparation of tablets
신코닌 10 ㎎Cinconin 10 mg
옥수수전분 100 ㎎ Corn starch 100 mg
유당수화물 100 ㎎ Lactose Carb 100 mg
스테아르산마그네슘 2 ㎎Magnesium stearate 2mg
상기의 성분을 혼합한 후, 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다.After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.
제제예Formulation example 3: 캅셀제의 제조 3: Manufacture of capsule
신코닌 10 ㎎Cinconin 10 mg
미결정셀룰로오스 3 ㎎ 3 mg of microcrystalline cellulose
유당수화물 14.8 ㎎Lactose carb 14.8 mg
스테아르산마그네슘 0.2 ㎎Magnesium Stearate 0.2 mg
상기의 성분을 혼합한 후, 통상의 캅셀제의 제조방법에 다라서 젤라틴캡슐에 충전하여 캅셀제를 제조하였다.After mixing the above components, it was filled in gelatin capsules according to the conventional method for producing a capsule to prepare a capsule.
제제예Formulation example 4: 주사제의 제조 4: Preparation of Injection
신코닌 10 ㎎Cinconin 10 mg
만니톨 180 ㎎Mannitol 180 mg
주사용 멸균 증류수 2974 ㎎Sterile distilled water for injection 2974 mg
인산일수소나트퓸 26 ㎎Monohydrogen phosphate 26 mg
상기의 성분을 혼합한 후, 통상의 주사제의 제조방법에 따라 1앰플당(2mL) 상기의 성분 함량으로 제조하였다.After mixing the above components, it was prepared in the above ingredient content per ampoules (2 mL) according to the conventional method for preparing injections.
제제예Formulation example 5:  5: 액제의Liquid 제조 Produce
신코닌 10 ㎎Cinconin 10 mg
이성화당 10 ㎎ Isomerized sugar 10 mg
만니톨 5 ㎎ Mannitol 5 mg
정제수 적량Purified water
레몬향 적량Lemon flavor
상기의 성분을 통상의 제조방법에 따라 정제수에 각각의 성분을 가하여 용해시키고 레몬향을 적량 가한 다음 정제수를 가하여 전체 100mL로 조절한 후 멸균시켜 갈색병에 충진하여 액제를 제조한다. The above components are dissolved in purified water according to a conventional preparation method, dissolved in purified water, and then lemon juice is added in an appropriate amount. After adjusting to 100 mL in total, sterilized and filled in a brown bottle to prepare a liquid formulation.
제제예Formulation example 6: 건강기능식품의 제조 6: Preparation of dietary supplements
신코닌 10 ㎎Cinconin 10 mg
비타민 혼합물 적량Vitamin mixture proper amount
비타민 A 아세테이드 70 ㎍70 μg of Vitamin A Acetate
비타민 E 1.0 ㎎Vitamin E 1.0 mg
비타민 B1 0.13 ㎎Vitamin B1 0.13 mg
비타민 B2 0.15 ㎎Vitamin B2 0.15 mg
비타민 B6 0.5 ㎎Vitamin B6 0.5 mg
비타민 B12 0.2 ㎍0.2 μg of vitamin B12
비타민 C 10 ㎎ Vitamin C 10 mg
비오틴 10 ㎍10 μg biotin
니코틴산아미드 1.7 ㎎Nicotinic Acid 1.7 mg
엽산 50 ㎍ Folate 50 ㎍
판토텐산 칼슘 0.5 ㎎Calcium Pantothenate 0.5mg
무기질 혼합물 적량Mineral mixture
황산제1철 1.75 ㎎Ferrous Sulfate 1.75 mg
산화아연 0.82 ㎎Zinc Oxide 0.82 mg
탄산마그네슘 25.3 ㎎Magnesium carbonate 25.3 mg
제1인산칼륨 15 ㎎Potassium monophosphate 15 mg
제2인산칼슘 55 ㎎ Dibasic calcium phosphate 55 mg
구연산칼륨 30 ㎎ Potassium citrate 30 mg
탄산칼슘 100 ㎎ Calcium Carbonate 100 mg
염화마그네슘 24.8 ㎎Magnesium chloride 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다.Although the composition ratio of the above-mentioned vitamin and mineral mixtures is mixed with a component suitable for a health food in a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method. The granules may be prepared and used for preparing a health food composition according to a conventional method.
제제예Formulation example 7: 건강음료의 제조 7: Manufacture of health drinks
신코닌 10 mgCinconin 10 mg
비타민 C 15 g15 g of vitamin C
비타민 E(분말) 100 g100 g of vitamin E (powder)
젖산철 19.75 gIron lactate 19.75 g
산화아연 3.5 g3.5 g of zinc oxide
니코틴산아미드 3.5 gNicotinamide 3.5 g
비타민 A 0.2 g0.2 g of vitamin A
비타민 B1 0.25 g0.25 g of vitamin B1
비타민 B2 0.3 g0.3 g of vitamin B2
정제수 정량Purified Water Quantification
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1 시간 동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2ℓ 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용한다.After mixing the above components according to a conventional healthy beverage production method, and then stirred and heated at 85 ℃ for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container sealed sterilization and then refrigerated and stored in the present invention For the preparation of healthy beverage compositions.
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만 수요계층이나, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.Although the composition ratio is mixed with a component suitable for a favorite beverage in a preferred embodiment, the composition ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and usage.
하기에 본 발명의 화합물을 함유하는 화장료 조성물의 제조예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Hereinafter, the preparation examples of the cosmetic composition containing the compound of the present invention will be described, but the present invention is not intended to limit the present invention, but is only intended to be described in detail.
제조예Production Example 1: 영양화장수( 1: nutritional cosmetics ( 밀크로션Milk Croissant ))
본 발명의 신코닌 2.0 중량%2.0% by weight of cinnamon of the present invention
스쿠알란 5.0 중량%Squalane 5.0 wt%
밀납 4.0 중량%Beeswax 4.0 wt%
폴리솔베이트60 1.5 중량%Polysorbate60 1.5 wt%
솔비탄세스퀴올레이트 1.5 중량%Sorbanthesquioleate 1.5 wt%
유동파라핀 0.5 중량%0.5% by weight of liquid paraffin
카프릴릭/카프릭트리글리세라이드 5.0 중량%Caprylic / Capric Triglycerides 5.0 wt%
글리세린 3.0 중량%Glycerin 3.0 wt%
부틸렌글리콜 3.0 중량%Butylene Glycol 3.0 wt%
프로필렌글리콜 3.0 중량%Propylene Glycol 3.0 wt%
카르복시비닐폴리머 0.1 중량%Carboxy vinyl polymer 0.1 wt%
트리에탄올아민 0.2 중량%0.2% by weight of triethanolamine
방부제, 색소, 향료 적량Preservatives, colorings, flavors
정제수 to 100 중량%Purified water to 100% by weight
상기의 배합비는 비교적 영양화장수에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상적인 화장품 분야에서의 제조방법에 따라 제조할 수 있다. Although the above-mentioned compounding ratio is mixed with a component suitable for nutritional longevity in a preferred embodiment, the compounding ratio may be arbitrarily modified, and can be prepared according to a conventional manufacturing method in the cosmetic field.
제조예Production Example 2: 유연화장수(스킨로션) 2: softening lotion (skin lotion)
신코닌 2.0 중량 %Cinchonine 2.0 wt%
글리세린 3.0 중량 %Glycerin 3.0 wt%
부틸렌글리콜 2.0 중량 %Butylene glycol 2.0% by weight
프로필렌글리콜 2.0 중량 %Propylene Glycol 2.0 wt%
카르복시비닐폴리머 0.1 중량 %Carboxy vinyl polymer 0.1 wt%
PEG 12 노닐페닐에테르 0.2 중량 %PEG 12 nonylphenylether 0.2% by weight
폴리솔베이트80 0.4 중량 % Polysorbate 80 0.4% by weight
에탄올 10.0 중량 %Ethanol 10.0 wt%
트리에탄올아민 0.1 중량 %Triethanolamine 0.1% by weight
방부제, 색소, 향료 적량Preservatives, colorings, flavors
정제수 to 100 중량 %Purified water to 100% by weight
상기의 배합비는 비교적 유연화장수에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상적인 화장품 분야에서의 제조방법에 따라 제조할 수 있다. The above blending ratio is mixed composition of a component suitable for a flexible softener in a preferred embodiment, but the blending ratio may be arbitrarily modified, it can be prepared according to the manufacturing method in the general cosmetic field.
제조예Production Example 3: 영양크림 3: nutrition cream
신코닌 2.0 중량 % Cinchonine 2.0 wt%
폴리솔베이트60 1.5 중량 % Polysorbate 60 1.5% by weight
솔비탄세스퀴올레이트 0.5 중량 %Solbitan Sesquioleate 0.5% by weight
PEG60 경화피마자유 2.0 중량 %PEG60 Cured Castor Oil 2.0% by weight
유동파라핀 10 중량 %10% by weight of liquid paraffin
스쿠알란 5.0 중량 %Squalane 5.0 wt%
카프릴릭/카프릭트리글리세라이드 5.0 중량 %Caprylic / Capric Triglycerides 5.0 wt%
글리세린 5.0 중량 %Glycerin 5.0 wt%
부틸렌글리콜 3.0 중량 %Butylene glycol 3.0% by weight
프로필렌글리콜 3.0 중량 %Propylene Glycol 3.0 Weight%
트리에탄올아민 0.2 중량 %Triethanolamine 0.2% by weight
방부제 적량Preservative
색소 적량Pigment amount
향료 적량Spices
정제수 to 100 중량 %Purified water to 100% by weight
상기의 배합비는 비교적 영양크림에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상적인 화장품 분야에서의 제조방법에 따라 제조할 수 있다. Although the above-mentioned compounding ratio is mixed with a component suitable for nourishing cream in a preferred embodiment, the compounding ratio may be arbitrarily modified, and can be prepared according to a conventional manufacturing method in the cosmetic field.
제조예Production Example 4: 마사지크림 4: massage cream
신코닌 1.0 중량 %Cinchonine 1.0% by weight
밀납 10.0 중량 %Beeswax 10.0 weight%
폴리솔베이트60 1.5 중량 % Polysorbate 60 1.5% by weight
PEG 60 경화피마자유 2.0 중량 % PEG 60 Cured Castor Oil 2.0% by weight
솔비탄세스퀴올레이트 0.8 중량 %Sorbanthesquioleate 0.8 wt%
유동파라핀 40.0 중량 %40.0% by weight of liquid paraffin
스쿠알란 5.0 중량 %Squalane 5.0 wt%
카프릴릭/카프릭트리글리세라이드 4.0 중량 %Caprylic / Capric Triglyceride 4.0 wt%
글리세린 5.0 중량 %Glycerin 5.0 wt%
부틸렌글리콜 3.0 중량 %Butylene glycol 3.0% by weight
프로필렌글리콜 3.0 중량 %Propylene Glycol 3.0 Weight%
트리에탄올아민 0.2 중량 %Triethanolamine 0.2% by weight
방부제, 색소, 향료 적량Preservatives, colorings, flavors
정제수 to 100 중량 %Purified water to 100% by weight
상기의 배합비는 비교적 마사지크림에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상적인 화장품 분야에서의 제조방법에 따라 제조할 수 있다. Although the above-mentioned compounding ratio is mixed with a component suitable for a massage cream in a preferred embodiment, the compounding ratio may be arbitrarily modified, and can be prepared according to a manufacturing method in the general cosmetic field.
제조예Production Example 4: 팩 4: pack
신코닌 1.0 중량 %Cinchonine 1.0% by weight
폴리비닐알콜 13.0 중량 %Polyvinyl alcohol 13.0 wt%
소듐카르복시메틸셀룰로오스 0.2 중량 %Sodium Carboxymethylcellulose 0.2% by weight
글리세린 5.0 중량 %Glycerin 5.0 wt%
알란토인 0.1 중량 %Allantoin 0.1 wt%
에탄올 6.0 중량 %Ethanol 6.0 wt%
PEG 12 노닐페닐에테르 0.3 중량 %PEG 12 nonylphenyl ether 0.3% by weight
폴리솔베이트60 0.3 중량 %Polysorbate60 0.3 wt%
방부제, 색소, 향료 적량Preservatives, colorings, flavors
정제수 to 100 중량 %Purified water to 100% by weight
상기의 배합비는 비교적 팩에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상적인 화장품 분야에서의 제조방법에 따라 제조할 수 있다. Although the above-mentioned compounding ratio is mixed with a component suitable for a pack in a preferred embodiment, the compounding ratio may be arbitrarily modified, and can be prepared according to a manufacturing method in the general cosmetic field.
제조예Production Example 6: 젤 6: gel
신코닌 0.5 중량 %Cinchonine 0.5 wt%
에틸렌디아민초산나트륨 0.05 중량 %0.05% by weight of ethylenediamine sodium acetate
글리세린 5.0 중량 %Glycerin 5.0 wt%
카르복시비닐폴리머 0.3 중량 %Carboxy vinyl polymer 0.3 wt%
에탄올 5.0 중량 %Ethanol 5.0 wt%
PEG 60 경화피마자유 0.5 중량 % PEG 60 Cured Castor Oil 0.5% by weight
트리에탄올아민 0.3 중량 %0.3% by weight of triethanolamine
방부제, 색소, 향료 적량Preservatives, colorings, flavors
정제수 to 100 중량 %Purified water to 100% by weight
상기의 배합비는 비교적 젤에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상적인 화장품 분야에서의 제조방법에 따라 제조할 수 있다. Although the above-mentioned compounding ratio is mixed with a component suitable for a gel in a preferred embodiment, the compounding ratio may be arbitrarily modified, and can be prepared according to a conventional manufacturing method in the cosmetic field.
상기 배합비는 비교적 화장료 조성물에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그외의 색채 화장품을 포함하는 다양한 용도의 화장품에 적용될 수 있는 것이고, 그 효능에 따라 인체에 얇게 도포하여 바를 수 있는 약제 즉, 연고로 제조에 이용될 수 있으며 수요계층이나, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.The blending ratio is a relatively suitable composition for the cosmetic composition in a preferred embodiment, but can be applied to cosmetics of various uses, including other color cosmetics, according to the efficacy that can be applied to a thin coating on the human body, that is, Ointment may be used for manufacturing, and the mixing ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and usage.

Claims (16)

  1. 신코닌(Cinchonine) 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 주름 개선 또는 탄력 증진용 화장료 조성물.Cinchonine (Cinchonine) or a cosmetic composition for improving skin wrinkles or elasticity comprising a cosmetically acceptable salt thereof as an active ingredient.
  2. 제1항에 있어서,The method of claim 1,
    상기 신코닌은 i)프로콜라겐(procollagen) 분비량 증가, ii) 기질금속단백질분해효소(matrixmetalloproteinase, MMP) 유전자 발현 감소, iii) ColⅠα1(collagen type Ⅰ alpha 1), ColⅠα2 또는 Col3α1 발현 증가 또는 iv) 엘라스틴(elastin) 유전자의 발현을 증가시키는 것을 특징으로 하는 피부 주름 개선 또는 탄력 증진용 화장료 조성물.The synonin is i) increased procollagen secretion, ii) decreased expression of matrix metalloproteinase (MMP) gene, iii) increased collagen type I alpha 1, ColIα2 or Col3α1 expression, or iv) elastin (elastin) Cosmetic composition for improving skin wrinkles or enhancing elasticity, characterized by increasing the expression of the gene.
  3. 제1항에 있어서,The method of claim 1,
    상기 조성물은 비타민 C, 레티노산, TGF(transforming growth factor), 동물 태반 유래의 단백질, 베툴린산 및 클로렐라 추출물로 이루어진 군에서 선택되는 1 이상의 피부주름 개선 성분을 추가로 포함하는 것을 특징으로 하는 피부 주름 개선 또는 탄력 증진용 화장료 조성물.The composition wrinkles skin further comprising at least one skin wrinkle improving component selected from the group consisting of vitamin C, retinoic acid, transforming growth factor (TGF), protein from animal placenta, betulinic acid and chlorella extract Cosmetic composition for improving or enhancing elasticity.
  4. 신코닌(Cinchonine) 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 보습 증진, 각질 제거, 홍반 억제 또는 피부광노화 개선용 화장료 조성물.Cinchonine (Cinchonine) or a cosmetic composition for improving skin moisturizing, exfoliation, erythema suppression or skin photoaging improvement comprising the cosmetically acceptable salt thereof as an active ingredient.
  5. 제4항에 있어서,The method of claim 4, wherein
    상기 조성물은 피부 표피층의 비후를 억제하는 것을 특징으로 하는 피부 보습 증진, 각질 제거, 홍반 억제 또는 피부광노화 개선용 화장료 조성물.The composition is a cosmetic composition for improving skin moisturizing, removing dead skin cells, suppressing erythema or improving skin photoaging, characterized in that to suppress the thickening of the skin epidermal layer.
  6. 제4항에 있어서,The method of claim 4, wherein
    상기 조성물은 피부 표피-진피 결합부위의 교원섬유(collagen fiber)망의 손상을 억제하는 것을 특징으로 하는 피부 보습 증진, 각질 제거, 홍반 억제 또는 피부광노화 개선용 화장료 조성물.The composition is a cosmetic composition for improving skin moisturizing, exfoliation, suppressing erythema or improving skin photoaging, characterized in that to inhibit the damage of the collagen fiber (collagen fiber) network of the skin epidermis-dermis.
  7. 신코닌(Cinchonine) 또는 이의 식품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 주름 개선 또는 탄력 증진용 건강기능성 식품 조성물.Health functional food composition for improving skin wrinkles or enhancing elasticity comprising Cinchonine (Cinchonine) or a food acceptable salt thereof as an active ingredient.
  8. 신코닌(Cinchonine) 또는 이의 식품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 보습 증진, 각질 제거, 홍반 억제 또는 피부광노화 개선용 건강기능성 식품 조성물.Health functional food composition for improving skin moisturizing, exfoliating, inhibiting erythema or improving skin photoaging, including cinchonine or a food acceptable salt thereof as an active ingredient.
  9. 신코닌(Cinchonine) 또는 이의 염을 유효성분으로 포함하는 조성물을 개체에 투여 또는 복용시키는 단계를 포함하는 피부 주름 개선, 탄력 증진, 피부 보습 증진, 각질 제거, 홍반 억제 또는 피부광노화 개선 방법.A method for improving skin wrinkles, enhancing elasticity, enhancing skin moisturizing, removing keratin, inhibiting erythema or improving skin photoaging, comprising administering or taking a composition comprising Cinchonine or a salt thereof as an active ingredient to an individual.
  10. 제9항에 있어서,The method of claim 9,
    상기 조성물은 i)프로콜라겐(procollagen) 분비량 증가, ii) 기질금속단백질분해효소(matrixmetalloproteinase, MMP) 유전자 발현 감소, iii) ColⅠα1(collagen type Ⅰ alpha 1), ColⅠα2 또는 Col3α1 발현 증가 또는 iv) 엘라스틴(elastin) 유전자의 발현을 증가시키는 것을 특징으로 하는 방법.The composition comprises i) increased procollagen secretion, ii) decreased matrix metalloproteinase (MMP) gene expression, iii) increased collagen type I alpha 1, ColIα2 or Col3α1 expression, or iv) elastin ( elastin) method for increasing expression of the gene.
  11. 제9항에 있어서,The method of claim 9,
    상기 조성물은 피부 표피층의 비후를 억제하는 것을 특징으로 하는 방법.Said composition inhibits thickening of the skin epidermal layer.
  12. 제9항에 있어서,The method of claim 9,
    상기 조성물은 피부 표피-진피 결합부위의 교원섬유(collagen fiber)망의 손상을 억제하는 것을 특징으로 하는 방법.The composition is characterized in that to inhibit the damage of the collagen fiber (collagen fiber) network of the skin epidermal-dermal junction.
  13. 신코닌(Cinchonine) 또는 이의 염을 유효성분으로 포함하는 조성물의 피부 주름 개선, 탄력 증진, 피부 보습 증진, 각질 제거, 홍반 억제 또는 피부광노화 개선 용도.Use for improving skin wrinkles, enhancing elasticity, enhancing skin moisturizing, exfoliating, inhibiting erythema or improving skin photoaging of a composition comprising cinchonine or a salt thereof as an active ingredient.
  14. 제13항에 있어서,The method of claim 13,
    상기 조성물은 i)프로콜라겐(procollagen) 분비량 증가, ii) 기질금속단백질분해효소(matrixmetalloproteinase, MMP) 유전자 발현 감소, iii) ColⅠα1(collagen type Ⅰ alpha 1), ColⅠα2 또는 Col3α1 발현 증가 또는 iv) 엘라스틴(elastin) 유전자의 발현을 증가시키는 것을 특징으로 하는 용도.The composition comprises i) increased procollagen secretion, ii) decreased expression of matrixmetalloproteinase (MMP) gene, iii) increased collagen type I alpha 1, ColIα2 or Col3α1 expression, or iv) elastin ( elastin) to increase the expression of the gene.
  15. 제13항에 있어서,The method of claim 13,
    상기 조성물은 피부 표피층의 비후를 억제하는 것을 특징으로 하는 용도.The composition is characterized in that to suppress the thickening of the skin epidermal layer.
  16. 제13항에 있어서,The method of claim 13,
    상기 조성물은 피부 표피-진피 결합부위의 교원섬유(collagen fiber)망의 손상을 억제하는 것을 특징으로 하는 용도.The composition is characterized in that it inhibits the damage of the collagen fiber (collagen fiber) network of the skin epidermal-dermal junction.
PCT/KR2018/003866 2017-04-03 2018-04-02 Composition for reducing skin wrinkles, moisturizing skin, improving skin elasticity, exfoliating skin, inhibiting erythema or reducing skin photoaging, containing cinchonine or salt thereof as active ingredient WO2018186643A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170043172A KR101787319B1 (en) 2017-04-03 2017-04-03 Composition comprising Cinchonine or as active ingredients for anti-wrinkle, skin moisturizing, improving skin elasticity, exfoliating, inhibiting erythema or improving skin photo-aging
KR10-2017-0043172 2017-04-03

Publications (1)

Publication Number Publication Date
WO2018186643A1 true WO2018186643A1 (en) 2018-10-11

Family

ID=60296694

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/003866 WO2018186643A1 (en) 2017-04-03 2018-04-02 Composition for reducing skin wrinkles, moisturizing skin, improving skin elasticity, exfoliating skin, inhibiting erythema or reducing skin photoaging, containing cinchonine or salt thereof as active ingredient

Country Status (2)

Country Link
KR (1) KR101787319B1 (en)
WO (1) WO2018186643A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114948787A (en) * 2022-06-15 2022-08-30 绽妍生物科技有限公司 Skin moisturizing composition, cosmetic containing composition and preparation method

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101787319B1 (en) * 2017-04-03 2017-10-18 연세대학교 산학협력단 Composition comprising Cinchonine or as active ingredients for anti-wrinkle, skin moisturizing, improving skin elasticity, exfoliating, inhibiting erythema or improving skin photo-aging
KR102557358B1 (en) * 2021-09-03 2023-07-19 스노우화이트팩토리(주) Cosmetic composition comprising Anemopsis californica extract for improving elasticity of skin and wrinkle

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003160433A (en) * 2001-11-27 2003-06-03 Shiseido Co Ltd Anti-aging skin preparation for external use
WO2009064492A1 (en) * 2007-11-14 2009-05-22 New York University School Of Medicine Quinoline compounds as melanogenesis modifiers and uses thereof
KR20150103503A (en) * 2014-03-03 2015-09-11 김윤규 Spingoliposome cosmetic composition with effect of proliferation of skin cells
KR20160009330A (en) * 2014-07-16 2016-01-26 천유화장품(주) Cosmetic composition for improving skin-aging
CN105796558A (en) * 2014-12-31 2016-07-27 天津大学 Use of cinchonine in preparation of anti-tumor drugs
KR101787319B1 (en) * 2017-04-03 2017-10-18 연세대학교 산학협력단 Composition comprising Cinchonine or as active ingredients for anti-wrinkle, skin moisturizing, improving skin elasticity, exfoliating, inhibiting erythema or improving skin photo-aging

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003160433A (en) * 2001-11-27 2003-06-03 Shiseido Co Ltd Anti-aging skin preparation for external use
WO2009064492A1 (en) * 2007-11-14 2009-05-22 New York University School Of Medicine Quinoline compounds as melanogenesis modifiers and uses thereof
KR20150103503A (en) * 2014-03-03 2015-09-11 김윤규 Spingoliposome cosmetic composition with effect of proliferation of skin cells
KR20160009330A (en) * 2014-07-16 2016-01-26 천유화장품(주) Cosmetic composition for improving skin-aging
CN105796558A (en) * 2014-12-31 2016-07-27 天津大学 Use of cinchonine in preparation of anti-tumor drugs
KR101787319B1 (en) * 2017-04-03 2017-10-18 연세대학교 산학협력단 Composition comprising Cinchonine or as active ingredients for anti-wrinkle, skin moisturizing, improving skin elasticity, exfoliating, inhibiting erythema or improving skin photo-aging

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114948787A (en) * 2022-06-15 2022-08-30 绽妍生物科技有限公司 Skin moisturizing composition, cosmetic containing composition and preparation method

Also Published As

Publication number Publication date
KR101787319B1 (en) 2017-10-18

Similar Documents

Publication Publication Date Title
WO2018186640A1 (en) Composition for reducing skin wrinkles, moisturizing skin, improving skin elasticity, exfoliating skin, inhibiting erythema or reducing skin photoaging, containing ocimene or salt thereof as active ingredient
WO2017146414A1 (en) Composition for skin moisturization and skin wrinkle alleviation, containing α-terpineol as active ingredient
WO2017222317A1 (en) Composition having effect of improving skin moisturization, removing skin keratin, improving skin elasticity, inhibiting erythema, improving skin wrinkles or improving skin photoaging, containing ionone or salt thereof as active ingredient
WO2018186643A1 (en) Composition for reducing skin wrinkles, moisturizing skin, improving skin elasticity, exfoliating skin, inhibiting erythema or reducing skin photoaging, containing cinchonine or salt thereof as active ingredient
WO2021137677A1 (en) Composition containing plant extract
WO2018186644A1 (en) Composition for reducing skin wrinkles, moisturizing skin, improving skin elasticity, exfoliating skin, inhibiting erythema or reducing skin photoaging, containing jasmone or salt thereof as active ingredient
WO2018186641A1 (en) Composition for reducing skin wrinkles, moisturizing skin, improving skin elasticity, exfoliating skin, inhibiting erythema or reducing skin photoaging, containing piperonal or salt thereof as active ingredient
WO2021261975A1 (en) Vegetable extract comprising vegetable collagen and vegetable mucin, and method for preparing same
WO2020122360A1 (en) Method for preparing enzyme-treated zizania latifolia turcz. extract having increased tricin content, and composition for whitening, wrinkle reduction, anti-inflammation, anti-allergy and moisturization, prepared thereby
WO2018004141A1 (en) Composition having effect of skin moisturization improvement, skin exfoliation, skin elasticity enhancement, erythema inhibition, skin wrinkle alleviation or skin photoaging alleviation, containing, as active ingredient, any one or more selected from group consisting of cymene, behenic acid, 2-methoxynaphthalene, thymol, and salts thereof
WO2024049120A1 (en) Cosmetic composition containing extract extracted by means of eco-friendly natural eutectic solvent
WO2017213346A1 (en) Composition containing diosmin or salt thereof as active ingredient and having skin moisturizing improvement, skin exfoliation, skin elasticity enhancement, erythema inhibition, skin wrinkle alleviation, or skin photoaging retardation effect
WO2018186639A1 (en) Composition for reducing skin wrinkles, moisturizing skin, improving skin elasticity, exfoliating skin, inhibiting erythema or reducing skin photoaging, containing ionol or salt thereof as active ingredient
WO2018070707A1 (en) Composition for preventing or treating muscle disease comprising decanal or pharmaceutically acceptable salt thereof as active ingredient
WO2017142265A1 (en) Composition containing adipic acid as active ingredient for skin wrinkle alleviation and skin elasticity enhancement
WO2014003232A1 (en) Composition comprising dendropanax morbifera léveille extract as active ingredient for promoting hair growth
WO2018236186A1 (en) Composition containing sesquiterpene derivative as active ingredient for prevention or treatment of muscle diseases
WO2018128479A1 (en) Composition for preventing or treating muscle diseases, comprising suberic acid or pharmaceutically acceptable salt thereof as active ingredient
WO2019059668A2 (en) Composition for skin, containing, as active ingredient, milk cream liquid fermented by lactic acid bacteria
WO2020085826A1 (en) Composition for alleviation of skin irritation induced by environmental pollution factors or for skin protection, containing nutmeg extract or macelignan as active ingredient
WO2014168433A2 (en) Material composition for promoting hair growth, gray hair melanin regeneration and skin regeneration
WO2020032435A1 (en) Hair loss-preventing or hair restoration-promoting composition containing yarayara as active ingredient
WO2019017677A9 (en) Composition comprising citral as effective ingredient for exhibiting effect of muscle strengthening, muscle enhancement, muscle differentiation, muscle regeneration, or sarcopenia suppression
WO2020040621A1 (en) Composition for promoting differentiation or proliferation of human adipose stem cells
WO2022250348A1 (en) Skin whitening use of cysteine derivative

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18781663

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18781663

Country of ref document: EP

Kind code of ref document: A1